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I.1. Pulmonary function and testing 
I.1.1. Pulmonary function 
I.1.1.1. Normal pulmonary function and defense 
The lungs are the major organs of the respiratory system. Their vital function 
is to supply the body with oxygen from the air. Therefore, ventilation, which 
is the process of inspiration and expiration, is essential. When we breathe in, 
air flows through the nose or mouth, down the pharynx, into larynx, and down 
the trachea (Figure 1). The air then comes to the right and left main bronchi, 
which then branch into smaller and smaller airways, to finally form 
bronchioles.[1] The bronchioles are lined with a layer of smooth muscles.[2] 
Air continues through these small airways until it finally reaches the tiny 
balloon-like air sacs, the alveoli. At the level of the alveoli the gas exchange 
takes place, with diffusion of oxygen into capillary blood.  
 
 
Figure 1 – Anatomy related to pulmonary function. When inhaling, air flows 
through the nose or mouth, down the pharynx, into larynx, down the trachea. The 
air then comes to the right and left main bronchi, which branch into smaller and 
smaller airways, to form bronchioles. Air continues through these small airways 
until it finally reaches the alveoli, where gas exchange takes place with the blood. 
Figure adapted from website of the College of Medicine, University of Florida.[3] 
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To maintain its structure and function, immunological and defense 
mechanisms protect the respiratory system against microorganism and 
noxious gases and particles. First innate, intrinsic defense is activated, 
including anatomical barriers, mucociliary clearance and professional 
phagocytes cells.[4] These, at their turn, will activate several mediators, 
resulting in an inflammatory cascade of cytokines and chemokines. 
Once innate host defense systems are activated, the adaptive, acquired 
immune response is regulated by B and T cells, which are 
lymphocytes.[5]  The two major types of T cells are helper T cells (Th) and 
cytotoxic T cells (TC). Th cells exist of three main subsets: Th1, Th2, and Th17. 
Type 1 and type 2 immune responses that are mainly regulated by Th1 and Th2 
cells, respectively.[6] Th1 cells primarily secrete interferon-γ (IFN-γ) and 
stimulate type 1 immunity. By contrast, Th2 cells mainly secrete the cytokines 
IL-4, IL-5 and IL-13, and stimulate type 2 immunity, which is characterized 
by high antibody titers and increased eosinophil counts. After antigen-
dependent activation, B cells can develop into plasma cells, which secrete 
antibodies, or immunoglobulins (Ig) specialized to target that antigen.[5] IgA 
is the predominant type in secretions.[7] 
I.1.1.2. Compromised pulmonary function 
Lung function may be compromised in case of obstructive lung disease, such 
as asthma and chronic obstructive pulmonary disease (COPD). Asthma is a 
heterogeneous disease, usually characterized by chronic airway inflammation. 
Asthma is defined by the history of respiratory symptoms such as wheeze, 
shortness of breath, chest tightness and cough that vary over time and in 
intensity, together with variable expiratory airflow limitation.[8] Airway type 
2 immune responses are mainly mediated by eosinophils, mast cells, 
basophils, Th2 cells, group 2 innate lymphoid cells and IgE-producing B cells. 
[6] Asthma is often triggered by allergens or irritants in the air. When these 
irritants enter the bronchioles, mast cells release an inflammatory mediator 
histamine, which causes the smooth muscles of the bronchioles to contract. 
Narrowing of the airways, or bronchoconstriction, while meant to keep foreign 
substances from entering the lungs, can restrict breathing, sometimes severely. 
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This can happen during an exacerbation, which is an acute worsening of the 
patient’s baseline respiratory symptoms. Exacerbations are caused or 
triggered by different factors including viruses, bacteria and air pollutants.[9] 
They are associated with acute, increased worsening of existing airway 
inflammation, causing deterioration of lung function.[9,10] 
 
COPD is a common, preventable and treatable disease that is 
characterized by persistent, usually progressive respiratory symptoms and 
airflow limitation that is due to airway and/or alveolar abnormalities usually 
caused by significant exposure to noxious particles or gases and influenced by 
host factors including abnormal lung development.[11] Included in those 
causing agents are environmental or occupational exposures to dust, as 
cigarette smoking but also exposure to organic and inorganic dust in non-
smokers. [12–14] Increased airway smooth muscle in COPD patients with 
progressing disease is negatively correlated with lung function.[15,16] The 
term ‘asthma-COPD overlap’ (ACO) is used to describe patients who have 
persistent airflow limitation together with clinical features of both asthma and 
COPD.[8,17] ACO is associated with more frequent exacerbations and poorer 
quality of life.[18,19] 
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I.1.2. Pulmonary function tests 
I.1.2.1. Spirometry 
Spirometry is the most common test to evaluate pulmonary function and 
outputs physiologic measurements. It can be used for screening of high-risk 
populations or as work-up for individuals with respiratory symptoms. It is a 
physiological test that measures air volumes when exhaling with maximal 
effort after a deepest inhalation possible. The volume of air produced during 
the first second of this exercise, is called the FEV1 (Figure 2). The total volume 
of air that can be forcibly exhaled, is the FVC. FEV1 and FVC are often plotted 
on spirometric curves.[20] A frequently used ratio of those two is the 
FEV1/FVC ratio, also named the Tiffeneau index, used to detect airflow 
limitation.[21] An obstructive disease is defined by a FEV1/FVC ratio is below 
the cutoff of 0.7. However, because the ratio varies with ageing, it should be 
confirmed by post-bronchodilator FEV1/FVC values below the lower limit of 
normal, especially in young individuals.[21,22] The severity of the disorder is 
determined by the FEV1 % predicted based on reference values derived from 
population-based cross sectional studies. 
 
A bronchodilator pulmonary function test (BD PFT) includes a spirometry 
before administration of a bronchodilator (pre-bronchodilator), followed by 
second spirometry after administration of a bronchodilator (post 
bronchodilator) such as salbutamol (albuterol). This test will assess 
bronchodilator responsiveness. A significant positive bronchodilator response 
is defined as a change in FEV1 and/or FVC from baseline being >12% and 
200 mL.[23] 
Another test reversible airflow obstruction is a bronchial provocation test. 
This test measures reduction of FEV1 in response to methacholine, histamine 
or exercise.[21,24]. The dose of methacholine or histamine producing a 20% 
reduction of FEV1 is a measure of bronchial responsiveness.[25] A 15-20% 
reduction of FEV1 during exercise or after a 10mg/mL doses of methacholine 
defines bronchial hyper-responsiveness.[26] 
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Figure 2 – Spirometric flow-volume (Panel A) and volume-time (Panel B) curves 
for a healthy 52-year-old male, who’s 188cm tall. In the flow-volume curve the 
well-defined peak in expiratory flow represents good initial effort. The expiratory 
portion of the curve can be found at the top and closing the loop back to 0 flow 
shows the inspiratory portion (bottom). The Forced Expiratory Volume in 1 second 
(FEV1) is indicated around 4.4L in the expiratory part of the flow-volume curve or 
at 1 second on the volume-time curve. The maximum volume of air that can be 
exhaled after a maximal inhalation, is the Forced Vital Capacity (FVC) of the 
spirometry. In the volume-time curve good initial effort is shown by a sharp 
increase in volume from time 0.  
Figure adapted from Crapo, NEJM, 1994. Reproduced with permission from 
Crapo RO. Pulmonary-Function Testing. N Engl J Med. 1994 Jul 7;331(1):25–30. 
Copyright Massachusetts Medical Society. 
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I.1.2.2. Quality of pulmonary function test 
 
Following American Thoracic Society/European Respiratory Society 
recommendations on standardized reporting for pulmonary function tests, 
spirometry measurements of FEV1 and FVC are graded on a scale between A 
and F.[27] The grading system informs the interpreter about the acceptability 
and repeatability. The acceptability criteria define a minimum of quality 
standards the results of FEV1 and FVC have to meet, including not being 
allowed to make certain critical errors. The repeatability criteria set maximum 
allowable differences between the two largest FVC values and the two largest 
FEV1 values. Grades A through C are considered as clinically useful. 
 
I.1.2.3. Screening spirometry testing 
 
As for primary care setting, hand-held office spirometers have been used since 
many years as a screening tool.[27,28] They are user-friendly, but require 
trained personnel to provide reproducible results. Hand-held spirometers are 
useful in offices of general practices. Analogously, for the longitudinal follow-
up of lung function, a handheld spirometer was used as part of the World Trade 
Center (WTC) health program at the Fire Department of the City of New York 
(FDNY).[29] 
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I.1.3. Lung function trajectories 
I.1.3.1. FEV1 trajectories 
When collecting multiple spirometry measurements longitudinally, we can 
analyze a FEV1 trajectory. Throughout childhood FEV1 increases to a 
maximum at an age around 20 years. There is evidence that there is a plateau 
phase between age 20 until 30-35 years (Figure 3). From middle age 
adulthood, the FEV1 declines around 30 mL/year in men and 25mL/year in 
women.[30] A greater than age-related (accelerated) decline in FEV1 despite 
a normal lung function at early adulthood, is one of the pathways found to lead 
to COPD, visualized as a red trajectory on Figure 3.[31]  
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Figure 3 – Lung function trajectories leading to chronic obstructive pulmonary 
disease (COPD). When attenuating a maximal lung function at early adulthood, a 
normal decline will result in an age-related FEV1 decline, whereas an accelerated, 
rapid decline will lead to COPD. In case of a lower maximum lung function at 
early adulthood, a moderate decline can preserve the lung function, but a greater 
decline will end in COPD. 
Figure adapted from Lange et al. NEJM, 2015. Reproduced with permission from 
Lange P, Celli B, Agustí A, et al. Lung-function trajectories leading to chronic 
obstructive pulmonary disease. N Engl J Med 2015;373:111-22. Copyright 
Massachusetts Medical Society. 
 
I.1.3.2. Risk factors for FEV1 decline 
As shown by the black trajectory of FEV1 in Figure 3, impaired lung growth 
an early lung function might also be a risk factor for developing COPD.[32] 
Lung growth and lung function in early life is a result of both genetic 
mechanisms and complex interactions between genetic makeup and a large 
number of environmental factors. A large number of environmental toxic 
agents have been implicated as having the potential to adversely affect normal 
lung development. There is strong evidence that in utero exposure to 
environmental agents, specifically tobacco smoke, is associated with adverse 
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respiratory outcome and this appears to be influenced by genetic makeup. 
Evidence of a gene-environmental interaction is found by showing that infants 
from mothers carrying polymorphisms of the GST gene were more susceptible 
to the adverse effects of smoking.[33] Moreover, polymorphisms in GST-
Omega genes interact with environmental tobacco smoke exposure both in 
utero and in adulthood and significantly affect FEV1 in adulthood.[34] 
Population-based studies have connected genes important for lung growth, 
such as ADAM33, with susceptibility to chronic obstructive pulmonary 
disease. These have been confirmed by patient studies.[35,36] Another study 
showed that SOX5, a gene necessary for lung development, is associated with 
chronic obstructive pulmonary disease, which suggest the development of the 
disease being in utero.[37] 
 
Risk factors for an accelerated decline in FEV1 leading to COPD despite a 
normal maximum at early adulthood (red trajectory on Figure 3) , are smoking, 
occupational exposures and heterozygote alpha-1-anti-trypsin 
deficiency.[30,38] A greater decline in FEV1 has also been observed in 
individuals with asthma.[39,31] Also, an increased frequency of pulmonary 
exacerbations was found to be associated with FEV1 decline.[40,41] 
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I.2. WTC cohort 
 
I.2.1. 9/11 disaster 
 
The terrorist attack on 11 September 2001 (9/11) caused the WTC towers to 
explode and collapse. This produced a huge dust cloud in Lower Manhattan 
in the first days after 9/11, containing building debris and products of 
combustion.[42] Many individuals, from residents, to commuters, rescue- and 
recovery and cleanup workers, got massively exposed to this dust. The FDNY 
operated a continuous rescue and recovery effort at the WTC site, involving 
approximately 11 000 firefighters. An increase in symptoms and incidence of 
post-9/11 diseases was observed. Among the FDNY rescue- and recovery 
cohort, a raise in lower respiratory symptoms and obstructive airway disease 
was found, besides a significant drop in FEV1 compared with pre-9/11 
screening spirometry measurements.[43,44,29,45,46] Furthermore, 
comorbidities such as chronic rhinosinusitis, gastro-esophageal reflux 
disorder, post-traumatic stress disorder and depression have been noted.[47–
51] 
I.2.2. Monitoring program and data collection 
 
Soon after 11 September 2001, the Fire Department of the City of New York 
(FDNY) instituted a medical monitoring program that performed screening 
spirometry tests (Figure 4). The program also collected demographic, 
exposure and respiratory symptom data via computer-based health 
questionnaires and body measurements form physical examination.[52] 
Additionally, FDNY began a treatment program at no cost to the participants. 
If indicated, individuals were sent to a hospital pulmonary laboratory for 
subspecialty pulmonary exams as post-bronchodilator pulmonary function test 
(PFT) or methacholine challenge test (MCT). Longitudinal data from these 
monitoring and treatment programs have gained insights in post-9/11 diseases 
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and treatment responses. A majority of FDNY firefighters also had pre-9/11 
spirometry tests and blood work. 
 
 
Figure 4 - Longitudinal data collection at Fire Department of the City of New York 
(FDNY) as part of the World Trade Center (WTC) Health Program. Soon after the 
disaster on 11 September 2001 (9/11) FDNY started a medical monitoring for 
rescue and recovery workers who were active at the WTC site between 11-
24/09/2001. At the monitoring exams a physical exam, health questionnaire and 
spirometry test were performed. When indicated, patients underwent an additional 
subspecialty pulmonary exam as a post-bronchodilator pulmonary function test or 
methacholine challenge test to test for bronchodilator responsiveness or 
hyperresponsiveness, respectively. 
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I.2.3. Demographics of the FDNY WTC cohort 
 
Of the FDNY rescue and recovery workers, approximately 11 000 were 
firefighters exposed to dust from working at the WTC site. Since the FDNY 
WTC-exposed firefighter cohort was less than 1% female, women were not 
included in most research studies.  
Table 1 shows demographics of WTC-exposed male firefighters who had at 
least one post-9/11 monitoring spirometry. The mean age on 9/11 was about 
40 years old. Two thirds never smoked. The majority race was white (94%). 
The proportion of individuals who had high intensity exposure, defined by 
arrival at the WTC site on the morning of 9/11, was about 17%, whereas 71% 
arrived the afternoon of 9/11 or the day after. The mean of first post-9/11 FEV1 
was 96.7 ± 13.8% predicted and the FEV1/FVC was 0.84 ± 0.06. By 2020, a 
big proportion (77%) of the cohort has retired, with a mean age of 50 years at 
their retirement. The mean of most recent FEV1 was 92.5 ± 14.5% predicted 
and the FEV1/FVC was 0.78 ± 0.06. 
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Table 1 – Demographics of WTC-exposed male firefighters (n = 10 172) containing 
first post-9/11 characteristics and measurements 
Variable 
Population 
n = 10 172 
Age on 9/11 (years), mean±SD 40.3 ± 7.4 
BMI (kg/m2), mean±SD 28.9 ± 3.5 
Smoking status, n (%)  
Never smokers 7 500 (73.7) 
Former smokers 1 453 (14.3) 
Current smokers 1 218 (12.0) 
Race, n (%)  
White 9 561 (94.0) 
Black 255 (2.5) 
Other 356 (3.5) 
WTC exposure level  
Morning of 9/11 1 673 (16.5) 
Afternoon of 9/11 or  
12 September 2001 
7 240 (71.2) 
13 to 24 September 2001 1 259 (12.4) 
Spirometry measurement, mean±SD  
FEV1 % predicted 96.7 ± 13.8 
Absolute FEV1, L 4.00 ± 0.68 
FEV1/FVC ratio 0.84 ± 0.06 
9/11 = 11 September 2001; SD = standard deviation; BMI = body 
mass index; WTC = World Trade Center; FEV1 = forced 
expiratory volume in 1 second; FVC = forced vital capacity 
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I.2.4. WTC-exposure and other risk factors of disease 
 
High WTC exposure, defined as initial arrival at the WTC site during the 
morning of 9/11, was found to be associated with a lower lung function 
(Figure 5).[45] WTC-exposure intensity, was also associated with physician-
diagnosed obstructive airways disease until September 2008.[53] After the 
first 7 years, WTC-exposure intensity was no longer significantly associated 
with incident disease even though elevated incidence of physician diagnosed 
lower airways disease has persisted. 
In sinus disease, high WTC exposure and elevated first post 9/11 blood 
eosinophil counts were found to be risk factors for chronic rhinosinusitis 
(CRS).[47] These factors also turned out to be predictors in CRS patients 
requiring sinus surgery. Furthermore, low IgA was associated with 
eosinophils in sinus surgery and not in individuals without sinus disease.[48] 
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Figure 5 – Longitudinal FEV1 trajectories stratified by WTC-exposure intensity. 
Individuals with high intensity exposure defined by arrival at the morning of 11 
September 2001 (9/11) were showing lower FEV1 values longitudinally. (Panel A) 
Actual FEV1 adjusted by age on 9/11, height, weight, sex, and race. (Panel B) FEV1 
% predicted adjusted by age on 9/11, and weight. Only never-smokers at the end 
of the study were included.  
Figure from Aldrich TK, Vossbrinck M, Zeig-Owens R, et al. Lung Function 
Trajectories in World Trade Center-Exposed New York City Firefighters Over 13 
Years. Chest 2016;149:1419–27. Copyright Elsevier. 
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I.2.5. Classification of post-9/11 lung injury 
 
When WTC-exposed firefighters had an abnormal screening FEV1 or when 
they experienced persistent respiratory symptoms, they were referred for 
additional work-up at a hospital-based pulmonary laboratory. This 
subspecialty pulmonary testing most often included a bronchodilator PFT 
and/or MCT, checking for bronchodilator responsiveness or bronchial 
hyperresponsiveness, respectively.[24,54] 
 
Bronchial hyperreactivity and obstructive airways disease (OAD) was a 
frequent finding post 9/11.[55,44] By 2008, 13% had received subspecialty 
pulmonary testing, with 59% having OAD based on meeting at least one of 
those criteria: an FEV1/FVC <0.76 (LLN), bronchodilator responsiveness, 
hyperreactivity, or an RV>120% predicted. The type of asthma that was seen 
was an irritant-induced asthma likely related to the exposure to WTC dust, 
resulting in negative allergy testing most of the time. A smaller proportion of 
44% of individuals with BD PFT showed an airflow limitation defined by 
FEV1/FVC<0.7.[46] Higher eosinophil concentrations were associated with 
incident airflow limitation. 
Categorizing all post-9/11 lung injury into a standard type of lung disease 
seems to be challenging. By 2014 only 1.6% of WTC-exposed firefighters had 
a persistent FEV1 < 70% predicted (Figure 6). [29] Although a proportion of 
around 13% of WTC-exposed firefighters are experiencing an accelerated 
(loss >64 ml/y) FEV1 decline by 2016 (red triangle curve on Figure 7). Higher 
blood eosinophil and neutrophil counts were both associated with accelerated 
FEV1 decline.[46] Reduced lung growth will less likely have been the pathway 
(black trajectory on Figure 3) to the development of accelerated decline in 
WTC firefighters, since there is a high demanding physical testing before 
onboarding as a firefighter [56,57] Most individuals experiencing an 
accelerated FEV1 decline still have an FEV1 within the normal range and 2/3rd 
lack evidence of asthma on subspecialty testing.[46] This means this type of 
airways disease does not yet meet the definition of asthma or COPD. 
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Figure 6 – Proportion of abnormal lung function in WTC-exposed Fire Department 
of New York City (FDNY) firefighters. Shown are data for nonsmoking FDNY 
firefighters who were at the World Trade Center site during the first 2 weeks after 
the attack of 11 September 2001 (9/11). The proportions of firefighters who had a 
forced expiratory volume in 1 second (FEV1) under the lower limit of the normal 
range (=the lowest 5th percentile of a reference population) or less than 70% of 
the predicted value are indicated. Data are shown for white workers and black 
workers only, since reliable predicted normal values were not available for other 
groups.  
Adapted from Aldrich et al., NEJM, 2010. Reproduced with permission from 
Aldrich TK, Gustave J, Hall CB, Cohen HW, Webber MP, Zeig-Owens R, Cosenza 
K, Christodoulou V, Glass L, Al-Othman F, Weiden MD, Kelly KJ, Prezant DJ. 
Lung function in rescue workers at the World Trade Center after 7 years. N Engl J 
Med. 2010 Apr 8;362(14):1263-72. Copyright Massachusetts Medical Society. 
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Figure 7 – Longitudinal FEV1 trajectories stratified by rate of FEV1 decline. A 
subgroup of WTC-exposed workers experiencing accelerated FEV1 decline defined 
by a loss >64 ml/year (red line with triangles).  
Adapted with permission of the American Thoracic Society. Copyright © 2021 
American Thoracic Society. All rights reserved. Zeig-Owens R, Singh A, Aldrich 
TK, Hall CB, Schwartz T, Webber MP, Cohen HW, Kelly KJ, Nolan A, Prezant DJ, 
Weiden MD. 2018. Blood Leukocyte Concentrations, FEV1 Decline, and Airflow 
Limitation. A 15-Year Longitudinal Study of World Trade Center–exposed 
Firefighters. Annals of the ATS. 15:173–83. Annals of the American Thoracic 
Society is an official journal of the American Thoracic Society. Readers are 
encouraged to read the entire article for the correct context at 
https://doi.org/10.1513/AnnalsATS.201703-276OC. The authors, editors, and The 
American Thoracic Society are not responsible for errors or omissions in 
adaptations. 
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I.3. Treatments containing inhaled corticosteroids (ICS) 
I.3.1. Inhaled corticosteroid (ICS) and inhaled corticosteroids / long-
acting beta-agonist (ICS/LABA) 
Corticosteroids are the most frequently prescribed anti-inflammatory therapy 
for obstructive airway disease.[58] The corticosteroid binds to the cytoplasmic 
glucocorticoid receptor, present in many cells of the lung. Consequently, the 
activated glucocorticoid receptor binds to DNA at the glucocorticoid response 
elements located on steroid-sensitive genes, inhibits transcription and 
synthesis of many proinflammatory cytokines (transrepression) and promotes 
synthesis of anti-inflammatory proteins (transactivation).[59,60] At a cellular 
level, corticosteroids reduce the number of eosinophils, T-lymphocytes, mast 
cells and dendritic cells in the airways (Figure 8) and reduce inducible nitric 
oxide production.[61] Since corticosteroids can interfere with the multiple 
inflammatory pathways, systemic administration has a lot of side effects. 
Topical application of corticosteroids via inhalation (ICS) has a better 
therapeutic index and is the cornerstone in current pharmacotherapy of asthma 
patients. [62–65] ICS is a controller therapy that reduces airway inflammation 
and hyperresponsiveness by altering the production of mediators associated 
with inflammatory cells in the airways.[66,67] Even in mild asthma a low dose 
ICS is recommended and recently there became more evidence to shift to as-
needed low dose ICS combined with the long-acting beta-agonist (LABA) 
formoterol.[8,68] Inhaled corticosteroids and long-acting beta-agonist 
(ICS/LABA) combination is the preferred therapy for moderate asthma and 
COPD with frequent exacerbations.[8,11]  
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Figure 8 – Action mechanisms of corticosteroids. Corticosteroids suppress the 
inflammation in the airways. They inhibit the recruitment of inflammatory cells into 
the airway by suppressing the production of chemotactic mediators and adhesion 
molecules and inhibit the survival in the airways of inflammatory cells, such as 
eosinophils, T cells and mast cells and dendritic cells. 
Figure adapted from Barnes PJ and Adcock IM. How do corticosteroids work in 
asthma?Annals of Internal Medicine. 2003;139:359. Copyright American College of 
Physicians.  
 
Beta-2-agonists are effective bronchodilators primarily to their ability to relax 
airway smooth muscle.[69] They exert their effects via their binding to the 
active site of beta-2-adrenoceptors on the smooth muscle, which triggers a 
signaling cascade that results in a number of events, all contributing to 
relaxation of the airway smooth muscle.[70] LABA’s are long-acting agents 
(duration of action more than 12 hours), which result in long-term 
improvement in lung function and are ideally suited as maintenance treatment. 
The working mechanisms of bronchodilators are to reduce airflow obstruction 
and decrease respiratory symptoms by reducing dynamic hyperinflation.[71]  
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I.3.2. Treatment for post-9/11 lung injury 
The data sources used for most post-9/11 treatment analyses in the FDNY 
WTC cohort consisted of electronic medical record (EMR) notes and 
pharmacy claims. Analyses of those data revealed 40% of WTC-exposed 
firefighters were prescribed an ICS/LABA combination by 2020. A 
proportion of 25% used an inhaler for at least 2 years post 9/11 (Figure 9). The 
majority of those (86%) was on an inhaler containing ICS and LABA 
combination and 12% an ICS monotherapy. 
 
Figure 9 – Distribution of inhaler use for at least 2 years in WTC-exposed 
firefighters (N =10 172). A proportion 25% of WTC-exposed firefighters used an 
inhaler for at least 2 years post-9/11. The majority of inhaler users was on a 
combination of inhaled corticosteroids and long-acting beta-agonist (ICS/LABA) 














Inhalers for ≥ 2 years:
; <0.5%
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I.3.3. Treatment response 
I.3.3.1. Outcome measures 
There are several respiratory outcomes that can be examined to evaluate the 
effect of a particular treatment. The choice of the outcome measure(s) depends 
on the model of action or the indication of the treatment. Often assessed in 
obstructive lung diseases are spirometric endpoints, such as FEV1. When lung 
function has been monitored longitudinally, FEV1 trajectory measuring a 
change in FEV1 over time (slope), is another important outcome (Figure 3, 
Figure 5 and Figure 7). Other possible outcomes are rate of yearly 
exacerbations or change in respiratory symptoms. The latter one belongs to 
the group of patient-reported outcomes (PROs). PROs are directly reported by 
the patient without interpretation of the patient’s response by a clinician or 
anyone else. Despite being a subjective outcome, PROs gained importance 
since they reflect the patient’s health, quality of life, or functional status 
associated with health care or treatment.[72] Patient reported outcome 
measures (PROMs) are the tools or instruments used to measure PROs. Those 
often include validated questionnaires or scales. Well known in pulmonary 
medicine are the Asthma Control Test/Asthma Control Questionnaire in 
asthma and COPD Assessment Test, modified Medical Research Council 
dyspnea scale and Saint George's Respiratory Questionnaire in COPD.[73,74] 
In the WTC health program, a baseline demographic and exposure 
questionnaire was hand out first and followed by psychical and mental health 
questionnaire at each monitoring exam. 
 
I.3.3.2. Factors affecting treatment response 
Treatment response is the results of a multifactorial play of host factors, 
environmental factors, the drug-related factors. Host factors include many 
components such as the disease entity and patient-specific characteristics (age, 
race, sex, weight, genetics).[75] Disease entities are often classified by 
endotypes, that will classify patient in different categories based on their 
underlying molecular mechanisms.[76] Patient characteristics also contain 
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factors that determine the pharmacokinetics of the drug, such as genetic 
polymorphisms for drug-metabolizing enzymes and liver and kidney 
function.[77,78]   
 The environmental factors are modifiable components that mostly 
alter the intensity of the response, include allergens, smoking or exposure to 
noxious particles, infections, exercise, physiological impact, comorbidities, 
comedication and diet.[75] 
Among the drug-related factors, are the specific characteristics of the drug and 
adherence to the prescribed treatment. Drug characteristics will also contribute 
to the pharmacokinetics, such as the formulation determining the lung 
deposition, which is important in inhaler therapies.[79] Adherence to 
treatment will be discussed in more detail in section 3.4. 
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I.3.3.3. Biomarkers of treatment response 
Given the heterogeneity of clinical presentation, disease course and response 
to therapy, a targeted and more personalized approach is recommended. To 
better understand treatment effects and to improve the effectiveness of 
treatments, big data analyses and the identification of biomarkers are highly 
important. This led to the field of ‘precision medicine’, where treatments 
target the needs of individual patients based on certain characteristics, such as 
biomarkers, that distinguish a particular patient from other patients with 
similar clinical presentations.[80] The identification of endotypes, based on 
common biological mechanisms of disease, in obstructive lung disease, 
allowed the development of targeted therapies.[81] The recognition of two 
major asthma endotypes Th2-high (eosinophilic) and Th2-low 
(noneosinophilic) led to specific asthma treatments, such as anti-IgE, anti-IL5 
and anti-IL5R.[82] Although blood eosinophil count appears to be a promising 
biomarker for corticosteroid response in COPD, the selection of patients with 
a beneficial response to specific interventions is generally still 
unsatisfactory.[83] More steps to move towards precision medicine in COPD 
need to be taken.[84] 
In the WTC cohort, a subgroup of WTC-exposed firefighters is experiencing 
accelerated decline in FEV1, with a substantial number having continuing 
deterioration of lung function. To improve the effectiveness of treatments, it 
is crucial to identify characteristics or markers of individuals that can be 
targeted by certain treatments. 
I.3.3.4. Response to ICS containing therapies 
In COPD studies a favorable effect of ICS/LABA was seen on the annual 
exacerbation rate and health status defined by Sint-Georges respiratory 
questionnaire.[85] A recent trial studying COPD patients with exacerbations 
showed that triple therapy caused a reduction in mortality compared with 
long- acting muscarinic antagonist (LAMA)/LABA but not with 
ICS/LABA.[86,87] In asthma, ICS/LABA combination was found to improve 
overall asthma control, measured by improved symptoms, lung function and 
reduced exacerbations, and to improve quality of life.[88,89] Analyses of 
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databases suggest an important role for ICS containing therapies in reducing 
mortality in asthma.[90,91] 
The effect of pharmacotherapy on FEV1 decline has been questioned for over 
decades.[92] Two randomized controlled trials (RCTs) studying 
pharmacotherapeutic effects in COPD patients included FEV1 decline as a 
secondary endpoint. The post-hoc analyses showed a limited effect on the rate 
of FEV1 decline. The analyses from the TORCH (TOwards a Revolution in 
COPD Health) data showed an effect of ICS/LABA of 16 mL/year and these 
from the SUMMIT (Study to Understand Mortality and Morbidity in COPD) 
8 mL/year compared with placebo, respectively.[93,94] In asthma, hard 
evidence that ICS prevents long-term decline in lung function occurring in 
subgroup of asthma patients, is lacking.[91] 
I.3.4. Adherence to inhaler and other treatments 
Medication adherence is defined as the degree to which the person’s behavior 
corresponds with the agreed recommendations from a health care 
provider.[95] Adherence to a drug will highly influence the expected 
pharmacological effect of that drug and the ability to treat the patient’s 
disease.[96,97] There are different ways to measure adherence such as 
medication questionnaires, clinical assessments, objective measurements as 
drug (metabolite) testing in blood/urine or pill counts, or calculated ratios, 
based on the sum of days for which the medication is dispensed, such as 
‘proportion days covered’.[98] A questionnaire often used to estimate the 
adherence to inhaler treatment is the Test of the Adherence to Inhalers® (TAI) 
questionnaire.[99] Non-adherence can be intentional or non-intentional, when 
the patient is willing but not able to take the medication.[100]  
 
Non-adherence leads to adverse outcomes. Poor medication adherence as 
evaluated using a dose counter on the returned inhaler device, was associated 
with increased hospital admission and mortality in moderate to severe 
COPD.[101] Poor adherence, combining intentional and unintentional 
measures, has also been associated with low lung function, reduced cognition 
and advanced age.[102] A correct inhaler technique was found to be 
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fundamental for a good adherence.[96] The inhaler technique will also 
contribute to which fraction of the inhaled medication is deposited in the 
lungs.[78] The fraction not entering the lungs may lead to side effects, which 
can adversely affect the adherence. A Belgian pharmaceutical intervention 
trial resulting in an improved inhaler technique, had a positive effect on 
disease control in patients with asthma.[103] Better asthma control scores 
were also reported by patients with higher ICS adherence studied in a 
prospective cohort study.[104] In clinical setting, objective prescription refill 
data are used to estimate patients’ adherence. While imperfect, low adherence 
defined by pharmacy prescription data, was associated with increased 
exacerbation rates, health care costs and mortality in COPD.[105]  
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Once a patient has been diagnosed with a certain disease, prescribing the 
recommended treatment may seem like a guarantee for clinical improvement. 
However, the patient’s response is unique and is not entirely predictable from 
previously reported performances of the prescribed drug or treatment. Instead, 
the treatment response is the result of a complex interaction of host factors, 
environmental factors, and drug-related factors. Within the field of precision 
medicine, we aim to integrate these factors to improve patient outcomes. 
Focusing on lung diseases, the overall aim of this thesis is therefore to 
identify optimal treatment response to inhaled corticosteroids (ICS). The 
various factors contributing to this treatment response and assessed in this 
thesis have been graphically represented in Figure 10. A first focus was on 
host factors. More specifically, the disease type (endotype) has been 
characterized and screening parameters for individuals at risk have been 
identified. Second, the impact of environmental factors was studied, namely 
World Trade Center (WTC) exposure, defined by arrival at the WTC site and 
firefighting duty. In a third part, an important drug-related factor was studied, 
namely the impact of adherence to the prescribed treatment.  
 





Figure 10 – Schematic overview of factors affecting treatment response to inhaled 
corticosteroids (ICS) that have been evaluated in the scope of this thesis 
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As the first focus was on host factors, the disease entity and its underlying 
pathological mechanisms have been assessed. A first specific aim was to 
further characterize the type of lung injury of WTC-exposed firefighters and 
identify individuals at risk. Hereby, we targeted to link early biomarkers with 
subsequent disease risk. In Chapter III.1, we intended to identify early 
post-9/11 characteristics identifying individuals at risk for developing 
WTC-related lung injuries. Lung injuries were thereby defined by the 
initiation of prolonged ICS/long-acting beta-agonist (LABA) treatment. 
Blood eosinophil count was previously identified as a biomarker for airway 
inflammation and a risk factor for WTC-related chronic rhinosinusitis[48].  
We therefore studied blood eosinophils and their predictive power for 
WTC-related lung injuries. By assessing disease entities and clustering 
WTC-exposed firefighters, we aimed to identify characteristics associated 
with isolated asthma, isolated chronic obstructive pulmonary disease (COPD) 
and Asthma/COPD overlap (ACO) in Chapter III.2. Furthermore, we studied 
various blood biomarkers, including eosinophils, IgE and cytokines, and their 
relation to asthma, COPD or ACO, respectively.  
Immunoglobulin A (IgA) has an important role in airway immunity 
to defend against pathogens or foreign agents. Since low IgA is known to 
increase the risk for airway inflammation and COPD exacerbations,[106,107] 
we hypothesized that reduced serum IgA soon after WTC exposure was 
associated with subsequent airway injury. To evaluate this hypothesis, we 
studied the lung function in relation to counts of antibiotic and oral steroid 
courses. The lung function was thereby characterized by FEV1 trajectories and 
airflow obstruction. The medication usage was seen as a proxy for 
exacerbations of lung injury. (Chapter III.3)  
Longitudinal data leading up to the disease diagnosis is scarce. During 
15-year follow-up, a subgroup of WTC-exposed firefighters showed an 
accelerated FEV1 decline compared to their peers. The majority of this 
subgroup still has screening spirometry measurements within normal limits, 
even though the trajectory indicates that abnormal values are to be 
expected.[46] This can impact clinical decision making through the 
identification of at-risk individuals, in turn allowing to start treatment prior to 
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development of abnormal lung function. Therefore, we aimed to identify 
patient characteristics that predict WTC-related lung injury. These 
characteristics are based on the data collected during longitudinal routine 
medical monitoring. Lung injury was defined by initiation of prolonged 
ICS/LABA treatment. (Chapter III.4) Since patient-reported outcomes 
measures (PROMs) gain importance, longitudinal data on questionnaire-
based, patient-reported respiratory symptoms were analyzed, evaluating 
changes in dyspnea before and after ICS/LABA initiation. We thereby 
hypothesized that treatment initiation soon after WTC exposure would 
improve the trajectory of dyspnea. (Chapter III.1) 
 
A second specific aim of this thesis was to assess the impact of patient’s 
adherence to treatment response. The adherence is a very important factor 
since it will highly influence the desired pharmacological effect of the 
drug.[96,97] First,  a longitudinal study was performed to quantify adherence 
to ICS and the effects of ICS adherence on lung function trajectory. The 
pharmacotherapeutic effect on long term lung function decline remains 
questionable and the previously established effects have been rather 
small.[93,94] However, since acute exacerbations are associated with lung 
function decline and ICS is effective in treating acute exacerbations, it was 
hypothesized that ICS treatment decreases the rate of lung function decline in 
WTC-exposed firefighters. (Chapter IV.1) Eventually, examining how this 
important drug-related factor is translated into clinical practice, the impact of 
an intervention in Belgian asthma patients was studied. Pharmaceutical 
counseling (PC) intervention trials have proven to improve adherence to 
controller medication and asthma control.[108–110] Our goal was to analyze 
national-level pharmacy claims data one year prior and one year after a 
pharmaceutical counseling intervention, looking at adherence to ICS and 
asthma control. The former was thereby defined by the change in ICS usage, 
the latter by use of other asthma-related drugs. We hypothesized that 
individuals with difficult-to-control asthma who received a PC intervention 
experienced an increase in ICS adherence and an improvement in asthma 
control. (Chapter IV.2) 
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III.1. Course of dyspnea before and after initiation of inhaled 




Inhaled corticosteroids in combination with long-acting beta-agonists 
(ICS/LABA) are commonly used to treat fixed and variable obstructive lung 
diseases.[88,111–115] Current treatment guidelines are based on clinical trials 
with restricted data before ICS/LABA initiation. Research on the trajectories 
of respiratory symptoms before and after ICS/LABA initiation is limited. 
FDNY rescue/recovery workers experienced a massive irritant exposure after 
the collapse of the World Trade Center (WTC) on September 11, 2001 (9/11), 
resulting in increased rates of respiratory symptoms, as well as an acute drop 
in lung function associated with reactive airway disease and fixed airflow 
obstruction.[29,42,44,46,116–118] Using longitudinal data on respiratory 
symptoms, the aims of the present study were to analyze changes in dyspnea 
before and after ICS/LABA initiation and to determine whether time between 






The source population consisted of 9 638 male firefighters who were 
employed by FDNY on 9/11, first arrived at the WTC site between 11 and 24 
September 2001, and underwent at least three routine medical monitoring 
examinations between 11 September 2001 and 10 September 2018. The study 
population (N = 1 073; 11% of the source population) consisted of those who 
had ICS/LABA treatment for longer than 2 years after 9/11 and had at least 
one modified Medical Research Council (mMRC) dyspnea scale score [119] 
before and at least two mMRC scores after ICS/LABA initiation. The study 
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population completed 7 835 medical monitoring questionnaires, including 
mMRC scores, between 1 August 2005 and 10 September 2018. Written 
informed consent was provided by all participants. 
 
Demographics, height, weight, smoking status, initial arrival time at the WTC 
site (WTC exposure level), and spirometric measurements were retrieved from 
the FDNY employee database and/or assessed during routine medical 
monitoring examinations. Medication data were obtained from the FDNY 
electronic medical record and/or pharmacy claims data. Treatment duration 
was defined as the interval between first and latest fill dates of ICS/LABA. 
Multivariable-adjusted logistic regression determined variables associated 
with being in the study population of ICS/LABA-treated individuals versus 
not receiving ICS/LABA treatment (N = 6 721). Individuals classified as 
“responders” to ICS/LABA were those who had an mMRC slope less than 0 
after treatment initiation; “nonresponders” had an mMRC slope greater than 
or equal to 0. Longitudinal mMRC scores in responders and nonresponders 
were estimated using linear mixed effects models with random intercepts, with 
categorized year from ICS/LABA initiation, age, body mass index (BMI), and 
race as fixed effects. Multivariable logistic regression assessed pretreatment 
mMRC and time from 9/11 to treatment initiation as predictors for treatment 
response, adjusting for age and BMI pretreatment, race, ever smoking status, 
and WTC exposure level.  
 
Data analyses were performed using SAS version 9.4 software (SAS Institute). 
Figures were created with Prism 8 software (GraphPad Software). 
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III.1.3. Results 
 
The study population included 1 073 individuals who received ICS/LABA 
therapy for more than 2 years and had at least one mMRC score before and 
two mMRC scores after ICS/LABA initiation. The mean (± standard 
deviation) numbers of mMRC scores were 4 (± 2) before ICS/LABA initiation 
and 6 (± 3) after ICS/LABA initiation. Individuals from the study population 
had higher WTC exposure, first post-9/11 mMRC score, blood eosinophils, 
and BMI and lower first post-9/11 lung function than those who did not 
receive ICS/LABA treatment (Figure 11). 
 
 
Figure 11 – Forest plot showing variables associated with being included in the 
study population and receiving inhaled corticosteroid (ICS)/long-acting 
beta-agonist (LABA) treatment for longer than 2 years versus not receiving 
ICS/LABA treatment (N = 7 777). Results shown are from a multivariable logistic 
regression analysis performed to determine the associations between first post-
9/11 medical monitoring data and ICS/LABA treatment for longer than 2 years 
(odds ratios and 95% confidence intervals [bars]); data are also adjusted for race. 
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Responders (571 of 1 073; 53%) were more likely to be ever smokers (36% 
vs. 33%) but had pretreatment lung function similar to that of nonresponders 
(FEV1 % predicted, 89.3 ± 4% vs. 89.2 ± 13.7%; FEV1/FVC ratio, 
77.3 ± 6.0% vs. 76.8 ± 6.4%). Nonresponders (502 of 1 073; 47%) had a 
gradual rise in mMRC scores starting 11 years after WTC exposure (Figure 
12A), culminating in worse dyspnea score at the end of longitudinal follow-
up (1.55; 95% CI from 1.40 to 1.70; vs. 0.79; 95% CI from 0.64 to 0.94, 
respectively). When we assessed dyspnea trajectory relative to treatment 
initiation (Figure 12B), we observed that responders had a sharp increase in 
mMRC scores before treatment and a subsequent decrease. Non-responders, 
however, had a gradual rise in mMRC scores before treatment initiation, 
which continued to increase during treatment.  
 
In an adjusted multivariable model, increased time between 9/11 and 
treatment initiation was a strong predictor of nonresponse to therapy (Table 
2). A higher pretreatment mMRC, however, was significantly associated with 
a favorable response to treatment. 
 
Table 2 – Multivariate logistic regression predicting response to ICS/LABA treatment 
(N = 1 073) 
Variable OR 95% CI P Value 
Time from 9/11 to treatment initiation, 
per 5 years 0.43 0.34 0.55 <0.001 
mMRC scorea, per 1 point  1.21 1.10 1.33 <0.001 
Agea, per 10 years 1.06 0.87 1.28 0.60 
Smoking, ever vs. never 1.17 0.89 1.53 0.26 
BMIa, per 5 units  1.05 1.01 1.08 0.005 
WTC-exposure,   
                    high exposure (Ref: low) 0.74 0.45 1.22 0.24 
       intermediate exposure (Ref: low) 0.74 0.48 1.13 0.16 
apre-treatment 
 

















Figure 12 – Longitudinal modified Medical Research Council (mMRC) dyspnea 
scale scores and 95% confidence intervals in linear mixed effects models, stratified 
by responder type. mMRC scores were estimated using linear mixed effects models 
with random intercepts, with categorized year, age, body mass index, and race as 
fixed effects. The trajectory of the responder group is shown as a solid blue line, 
and the trajectory in the non-responders is shown as a broken red line. (A) 
Trajectories of mMRC scores relative to 11 September 2001 (9/11). 
Non-responders had a gradual rise in mMRC scores starting 11 years after WTC 
exposure, culminating in worse dyspnea score at the end of longitudinal follow-up. 
(B) Trajectories of mMRC scores relative to treatment initiation. Responders had 
a sharp increase in mMRC scores before treatment, followed by a subsequent 
decrease. Non-responders, however, had a gradual rise in mMRC scores before 
treatment initiation, which continued to increase after inhaled corticosteroid/long-
acting b-agonist (ICS/LABA) initiation. 
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III.1.4. Discussion & Conclusion 
 
This study produced longitudinal, patient-reported data on dyspnea from 
1 073 previously healthy WTC-exposed firefighters who received more than 
2 years of ICS/LABA treatment. The risk factors for treatment were similar to 
risk factors for obstructive airway disease in this cohort.[29,44,46,116] We 
observed heterogeneity in dyspnea response, with only 53% of treated 
individuals responding to treatment. We found that responders had rapidly 
increasing dyspnea, as defined by mMRC score, in the 3 years before 
treatment initiation. Notably, in responders, dyspnea improved for 5 years 
after treatment initiation, returning to a level similar to baseline. Non-
responders had gradually increasing dyspnea in the 3 years before treatment, 
which continued to increase during the first 5 years after treatment initiation. 
This finding suggests that clinical trials with patient-reported outcomes may 
benefit from longer follow-up than that used in most randomized clinical 
trials. Our study revealed pronounced differences in the trajectory of dyspnea 
in responders and non-responders to ICS/LABA treatment. Responders 
presented earlier after WTC exposure, and higher pre-treatment mMRC score 
predicted favorable treatment response, whereas non-responders had a longer 
time between WTC exposure and symptom onset or treatment initiation. This 
difference in onset of symptoms suggests that non-responders might have a 
different endotype of obstructive airway disease that is less responsive to ICS/ 
LABA therapy. The lack of response to ICS/LABA therapy in those with later-
onset dyspnea might be indicative of a less inflammatory type of disease. 
 
 Host-Factors | Page 43  
 
One limitation of this study may include generalizability to other affected 
individuals, because this single-center study of a massively dust-exposed 
cohort included only previously healthy males. We also acknowledge that 
there may be unmeasured confounding, which is possible in all observational 
studies. In addition, although regression to the mean might also contribute to 
the difference in symptom score trajectories between responders and 
non-responders, the greater symptom burden of non-responders at the end of 
follow-up suggests that regression to the mean is unlikely to be the sole or 
even main explanation for the observed effect. 
 
In conclusion, this longitudinal study showed that almost half of irritant-
exposed patients had worsening dyspnea after ICS/LABA initiation. 
Treatment benefited more symptomatic individuals who initiated ICS/LABA 
treatment sooner after WTC exposure. 
 
 
Reprinted with permission of the American Thoracic Society.  Copyright © 
2021 American Thoracic Society. All rights reserved. Putman B, Lahousse L, 
Singh A, Zeig-Owens R, Hall CB, Fazzari MJ, Schwartz T, Webber MP, Cohen 
HW, Prezant DJ, Weiden MD. 2020. Dyspnea and Inhaled Corticosteroid and 
Long-acting β-Agonist Therapy in an Occupational Cohort: A Longitudinal 
Study. Annals of the ATS. 17(6):770–3. Annals of the American Thoracic 
Society is an official journal of the American Thoracic Society. 
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III.2. Characterization of asthma, COPD and asthma/COPD 




The collapse of the World Trade Center (WTC) on 11 September 2001 (9/11), 
exposed the FDNY rescue and recovery workers to caustic dust and products 
of combustion.[42] Subsequently, WTC-exposed rescue and recovery workers 
had high rates of airway injury, including excessive loss of lung function,[29] 
obstructive ventilatory defect,[44] and airway hyperreactivity.[45] 
Firefighters with elevated post-exposure blood eosinophil concentrations were 
at increased risk of developing COPD.[46] 
 
Asthma/COPD overlap is a recently defined endotype of COPD,[120–122] 
with patients experiencing a poorer quality of life and higher mortality 
compared with patients who have either isolated-COPD or isolated 
asthma.[123–125] Risk factors for asthma/COPD overlap are poorly defined, 
but among those with smoking-related COPD, elevated eosinophils in sputum 
and blood are biomarkers for this condition.[126,127] Longitudinal studies are 
needed to define risk factors for asthma/COPD overlap.[128] 
 
The aim of the present study was to determine early predictors of 
asthma/COPD overlap among WTC-exposed firefighters with at least one 
post-9/11 clinically indicated pulmonary function test (PFT) with 
bronchodilator (BD) measurement (N = 2 137). The main predictors of interest 
were blood biomarkers collected during participants’ post-9/11 FDNY 
medical monitoring examination. We also examined these measurements in 
association with isolated-asthma and with isolated-COPD as a way to 
understand the unique predictors of asthma/COPD overlap. 
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III.2.2. Methods 
III.2.2.1. Study population 
The source population consisted of 9 598 male firefighters who were actively 
employed by the FDNY on 9/11; first arrived at the WTC between 11 
September 2001 and 24 September 2001; and had ≥ 3 post-9/11 FEV1 
measurements from routine medical monitoring PFTs taken at FDNY.[46] A 
subset of this population received at least one clinically indicated BD-PFT 
performed according to American Thoracic Society standards[129] at a 
hospital-based pulmonary function laboratory between 11 September 2001 
and 10 September 2017. We excluded 57 participants whose BD-PFT 
occurred before their first post-9/11 medical monitoring examination. The 
final study population included 2 137 firefighters (Figure 13). 
 
Participants provided written informed consent. The Montefiore Medical 
Center (FWA #00002558)/Albert Einstein College of Medicine (FWA 
#00023382) Institutional Review Board approved this study. 
III.2.2.2. Baseline characteristics 
Demographic data were retrieved from the FDNY employee database. 
Participants’ height, weight, self-reported smoking status (current, former, or 
never-smoker), and time of initial arrival at the WTC site were assessed during 
routine medical monitoring examinations at FDNY (both active duty 
firefighters and WTC-exposed retirees are scheduled to have a monitoring 
examination once every 12 to 18 months). Individuals were classified as 
having high (morning of 11 September 2001), moderate (afternoon on 11 
September 2001 to 12 September 2001), or low (13 September 2001 to 24 
September 2001) WTC exposure based on their WTC site arrival time.[45] 
Current and former smokers were grouped together as ever-smokers in these 
analyses. Those who consistently self-reported no cigarette smoking were 
classified as never-smokers. 
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Figure 13 – Firefighters who participated in the asthma/COPD overlap study. 
Shown is the source population of male firefighters who were employed by the 
FDNY on 11 September 2001 (9/11), present at the WTC site between 11 September 
2001 and 24 September 2001, and had at least three routine monitoring PFTs taken 
between 11 September 2001 and 10 September 2017 for FEV1 slope measurement. 
The final study population included those who had received a post-9/11 clinically 
indicated PFT with BD measurement. The serum biomarker population was a 
subgroup who had biomarkers measured on serum drawn between Oct 2001 and 
Feb 2002 
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III.2.2.3. Blood and serum biomarkers 
Eosinophil concentration was measured from blood drawn shortly after 9/11, 
during the first post-9/11 monitoring examination. The median first post-9/11 
blood draw date was 10 January 2002 (interquartile range: 26 November 2001 
to 27 December 2002). We also had pre-9/11 blood data (eosinophil 
concentration) for the 1 008 participants who had blood drawn at a pre-9/11 
monitoring examination. Serum biomarkers from the first post-9/11 blood 
draw, including IgE and cytokines, were available for a subgroup of the study 
cohort (N = 215). Serum was stored at –80°C; IL-4 and interferon (IFN)-γ 
were assayed with Millipore Sigma HSTCMAG28SPMX21 and IgE with 
HGAMMAG-303E. 
III.2.2.4. Pulmonary Function 
Participants’ most recent BD-PFT from the 11 September 2001 to 10 
September 2017 period provided the pre- and post-BD FEV1 and FVC 
measurements used to define our main outcome. A BD response of > 12% and 
200 mL increase from baseline FEV1 diagnosed asthma.[130] COPD was 
defined according to the Global Initiative for Obstructive Lung Disease 
(GOLD) criteria, which requires a FEV1/FVC ratio < 0.7 on a post-BD 
PFT.[121] We classified individuals who had a BD response and FEV1/FVC 
≥ 0.7 as having isolated-asthma, and those who had FEV1/FVC < 0.7 and no 
BD response as having isolated-COPD. Individuals who met the criteria for 
both asthma and COPD had asthma/COPD overlap. 
 
Total lung capacity (TLC) and residual volume (RV) measurements were also 
available from the BD-PFT data; these were measured prior to BD 
administration. We used spirometric measurements from 22 737 routine 
monitoring PFTs (always done without BD) taken between 11 September 
2001 and 10 September 2017 to assess post-9/11 FEV1 trajectories. FEV1 
values from post-9/11 monitoring PFTs that occurred prior to the BD-PFT 
were used to determine whether patients with asthma and/or COPD had 
accelerated (> 64 mL/y) or expected (≤ 64 mL/y) FEV1 decline post-9/11 but 
prior to our outcome determination; for individuals who had neither diagnosis, 
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all post-9/11 FEV1 values were included in the FEV1 decline rate calculation. 
Pre-9/11 FEV1 and FVC measurements. were available from 1 265 
spirometries performed at FDNY monitoring in the year prior to 9/11 (11 
September 2000 to 10 September 2001). 
III.2.2.5. Statistical Analysis 
Demographic and other characteristics of the study population and serum 
biomarker subgroup were assessed as proportions and means ± SD, with 
independent sample Student t tests or χ2 tests used to evaluate differences, as 
appropriate. Longitudinal FEV1 % predicted, FEV1/FVC ratio, and post-9/11 
rate of FEV1 change were estimated in four subsets of the population defined 
according to outcome (isolated-asthma, isolated-COPD, asthma/COPD 
overlap, or neither condition) using linear mixed effects models with random 
intercepts. Participants’ age on 9/11, height, and race were included as fixed 
effects in the models with the absolute FEV1 or FEV1/FVC ratio as the 
outcome. Mean FEV1 % predicted and FEV1/FVC ratio values in the four 
groups were estimated for each 1-year period between 11 September 2000 and 
10 September 2017, and mean rates of FEV1 change were determined by using 
the post-9/11 spirometry data. 
 
Log-rank Mantel-Cox tests were performed to examine the univariable 
associations of post-9/11 FEV1 trajectory (accelerated vs expected FEV1 
decline), eosinophil concentration, and smoking status with incident 
asthma/COPD overlap, followed by multivariable marginal Cox regression 
models for multiple events to evaluate shared and distinct risk factors for 
isolated-asthma, isolated-COPD, and asthma/COPD overlap. Censoring 
occurred at the time of the BD-PFT. Blood eosinophil concentration was 
assessed first as a binary variable (≥ 300 cells/µL vs < 300 cells/µL) and then 
as a continuous variable. Two sensitivity analyses were conducted: one that 
excluded individuals with an FEV1/FVC ratio < 0.7 on a pre-9/11 monitoring 
PFT (N = 69) and another that examined the relationship between pre-9/11 
eosinophil concentration and the outcomes of interest (N = 1 008). Absolute 
 Host-Factors | Page 49  
change in eosinophil concentration from pre-9/11 to post-9/11 was also 
investigated. 
 
A multivariable-adjusted Cox regression analysis for multiple events data was 
also performed in the serum biomarker subpopulation (N = 215) to determine 
whether log2-transformed serum IgE and 21 cytokines were associated with 
isolated-asthma, isolated-COPD, or asthma/COPD overlap. After Bonferroni 
correction, the significance cutoff for the serum biomarker analyses was set at 
a two-sided P value of 0.0024. For all other analyses, reported P values are 
two-sided and considered significant at the < 0.05 level. Multivariable models 
included age, race, smoking status, WTC exposure, first post-9/11 FEV1/FVC 
ratio, and BMI as covariates. Covariates were selected based on theory. Data 
analyses were performed by using SAS version 9.4 (SAS Institute, Inc). 
Figures were created by using Prism 7 (GraphPad Software). 
 
III.2.3. Results 
III.2.3.1. Baseline characteristics 
Demographic and other characteristics of the 2 137 firefighters with clinically 
indicated post-9/11 BD-PFT in the final study population (Figure 13) and 
those without BD-PFT are presented in Table 3. Compared with WTC-
exposed firefighters who did not have a BD-PFT, the study population was 
slightly different in that it was older, had a higher BMI and post-9/11 blood 
eosinophil 
concentration, and a greater proportion of ever-smokers. 
 
These differences were more pronounced in those who would develop a post-
BD FEV1/FVC ratio < 0.70. The serum biomarker subgroup was similar to the 
study population, with the exception of having a smaller proportion of ever-
smokers. 
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III.2.3.2. Lung function on monitoring and BD-PFTs 
Clinically indicated BD-PFT diagnosed isolated-asthma in 202 individuals 
(9.5%), isolated-COPD in 215 (10.1%), and asthma/COPD overlap in 99 
(4.6%) (Figure 14). At the time of BD-PFT, the asthma/COPD overlap 
subgroup had a lower pre-BD FEV1 % predicted, lower pre-BD FEV1/FVC 
ratio, and higher RV/TLC ratio than any other diagnostic category (Table 4). 
BD response was similar in patients with asthma/COPD overlap and isolated-
asthma (22.6 ± 13.3% vs 19.9 ± 12.8% increase in FEV1, respectively; 




Figure 14 – Asthma/COPD overlap in WTC-exposed firefighters who had a BD-
PFT. The Venn diagram demonstrates abnormalities on BD-PFTs obtained via the 
WTC treatment program. Isolated-asthma was diagnosed in 202 individuals who 
had FEV1 BD response of > 12% and 200 ml. Isolated-COPD was diagnosed in 
215 individuals who had a post-BD FEV1/FVC ratio < 0.70. Asthma/COPD 
overlap was diagnosed in 99 who had both an FEV1 BD response > 12% and 200 
ml, and an FEV1/FVC ratio < 0.70. The remainder of the study population (N = 1 
621) did not have a BD response or airflow limitation. 
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N = 7 404 
BD-PFT Study Population 





N = 235 P Value 
Post-BD 
FEV1/FVC ≥ 0.7 
N = 1 823 
Post-BD 
FEV1/FVC < 0.7 
N = 314 
Age on 9/11, y b 39.9 ± 7.6 40.5 ± 6.7 44.0 ± 6.8 41.0 ± 6.8 < 0.001 
BMI, kg/m2 b,c 28.7 ± 3.4 29.2 ± 3.5 28.5 ± 3.3 28.7 ± 3.3 < 0.001 
      
Smoking status, n (%) c   
Never 5 031 (67.9) 1 229 (67.4) 142 (45.2) 185 (86.0) < 0.001 
Former 2 143 (28.9) 542 (29.7) 148 (47.1) 22 (10.2)  
Ever 230 (3.1) 52 (2.9) 24 (7.6) 8 (3.7)  
      
Race, n (%)      
White 6 971 (94.2) 1 719 (94.3) 299 (95.2) 208 (96.7) < 0.001 
Black 174 (2.3) 36 (2.0) 10 (3.2) 4 (1.9)  
Hispanic 234 (3.2) 66 (3.6) 5 (1.6) 3 (1.4)  
Other 25 (0.3) 2 (0.1) 0 0  
      
WTC arrival time, n (%)   
Morning of 9/11 1 129 (15.3) 366 (20.1) 52 (16.6) 37 (17.2) < 0.001 
Afternoon on 9/11- 
12 Sept 2001 5 322 (71.9) 1 295 (71.0) 223 (71.0) 168 (78.1)  
13-24 Sept 2001 953 (12.9) 162 (8.9) 39 (12.4) 10 (4.7)  
 






N = 7 404 
BD-PFT Study Population 








N = 1 823 
Post-BD 
FEV1/FVC < 0.7 
N = 314 
Pre-9/11 spirometry 
FEV1, L b 4.43 ± 0.68d 4.38 ± 0.69e 3.94 ± 0.74f 4.32 ± 0.69g < 0.001 
FEV1 % 
predicted b 105.9 ± 13.3
d 104.3 ± 13.7e 95.2 ± 15.4f 103.3 ± 14.2g < 0.001 
FEV1/FVC b 0.85 ± 0.05d 0.85 ± 0.05e 0.78 ± 0.07e,f 0.84 ± 0.05g < 0.001 
      
Post-9/11 spirometry 
FEV1, L b,c 4.05 ± 0.65 3.96 ± 0.65 3.46 ± 0.73 3.92 ± 0.70 < 0.001 
FEV1 % 
predicted b,c 97.8 ± 12.9 95.4 ± 13.5 85.2 ± 15.3 94.4 ± 14.4 < 0.001 
FEV1/FVC b,c 0.84  ± 0.05 0.84 ± 0.05 0.74 ± 0.07 0.83 ± 0.06 < 0.001 
Post-9/11 FEV1 
slope, mL/yb -35.1  ± 30.8 -37.8 ± 32.4 -47.5 ± 36.3 -41.1 ± 37.0 < 0.001 
      
Blood eosinophil concentration 
Pre-9/11  
cells / µL 154 ± 109
h 162 ± 117i 186 ± 144j 153 ± 104k < 0.001 
Post-9/11  
cells / µL 184 ± 126
l 194 ± 136m 231 ± 175n 198 ± 132 < 0.001 
aANOVA or 2 test comparing values in first three columns 
bMean ± SD 
cValue on first post-9/11 monitoring examination 
dN = 6 836  eN = 1 686  fN = 285  gN = 209  hN = 3 295 iN = 857  jN = 151  kN = 109  lN = 1 815  mN = 1 815  
nN = 314 
 
Both the pre-9/11 and first post-9/11 FEV1 % predicted in each subgroup were 
on average ≥ 80% on monitoring PFTs but were lowest in those who went on 
to develop asthma/COPD overlap (Figure 15A). The FEV1/FVC ratio on the 
first post-9/11 monitoring PFT was also lowest in this subgroup (Figure 15B). 
The annual post-9/11 FEV1 loss in individuals with asthma/COPD overlap 
was similar to that of the COPD subgroup (47.6 mL/y [95% CI from 43.5 to 
51.6] and 47.2 mL/y [95% CI from 44.7 to 49.6], respectively), and greater 
than the rate of FEV1 loss in those with isolated-asthma (43.4 mL/y; 95% CI 
from 40.7 to 46.2) or neither outcome (36.8 mL/y; 95% CI from 35.9 to 37.6). 
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Pre-BD FEV1 % 
Predicted 67.3 ± 14.8 80.9 ± 13.5
a 82.3 ± 15.2a 96.9 ± 13.2a 
Post-BD FEV1 % 
Predicted 81.3 ± 14.5 96.2 ± 13.7
a 85.9 ± 15.0a 100.5 ± 13.5a 
     
Pre-BD FVC % 
Predicted 93.3 ± 15.8 87.1 ± 13.91 101.2 ± 15.1
a 98.3 ± 12.9a 
Post-BD FVC % 
Predicted 101.8 ± 14.0 96.0 ± 13.3
a 103.4 ± 15.1 98.5 ± 12.9a 
     
Pre-BD FEV1 / FVC 0.56 ± 0.08 0.73 ± 0.07a 0.62 ± 0.07a 0.77 ± 0.05a 
Post-BD FEV1 / FVC 0.62 ± 0.07 0.78 ± 0.05a 0.64 ± 0.06a 0.80 ± 0.05a 
Pre-BD RV / TLC 0.40 ± 0.10 0.33 ± 0.09a 0.33 ± 0.08a 0.28 ± 0.07a 
Data are expressed as mean ± SD 
aP < 0.05 vs asthma / COPD overlap subgroup 






Figure 15 – Lung function over time. (A) Mean ± SEM (SEM not shown if it is 
smaller than the size of the symbol) FEV1 % predicted in each year between 11 
September 2000 and 10 September 2017 in the asthma/COPD overlap (orange), 
isolated-COPD (gray), isolated-asthma (blue), and asthma-free and COPD-free 
(red) groups. The vertical line at 0 represents 11 September 2001. The number of 
spirometries per year is shown below the x-axis. (B) Mean FEV1/FVC ratio in the 
aforementioned groups in each year, adjusted for race, height, and age, using the 
same number of spirometries per year as shown in panel A. 
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III.2.3.3. Risk factors for asthma/COPD overlap 
Univariable analyses showed that the incidence of asthma/COPD overlap was 
elevated in participants with post-9/11 eosinophil concentration ≥ 300 
cells/µL (HR, 1.69; 95% CI from 1.00 to 2.81; P < 0.05) (Figure 16A), those 
with a history of smoking (HR, 1.67; 95% CI from 1.11 to 2.50; P = 0.02) 
(Figure 16B), and those experiencing post-9/11-accelerated FEV1 decline 
(HR, 2.05; 95% CI from 1.22 to 3.43; P = 0.006) (Figure 16C). In 
multivariable marginal Cox regression models for multiple events, 
asthma/COPD overlap was predicted by eosinophil concentration ≥ 300 
cells/µL (Table 5). Eosinophil concentration was not significantly associated 
with isolated-asthma or isolated-COPD. When isolated asthma and 
asthma/COPD overlap were compared directly, asthma/COPD overlap was 
still associated with elevated eosinophils (Table 6). Results were similar if 
analyses were restricted to those who had eosinophils measured < 15 months 
following 9/11 (data not shown). A unique risk factor for isolated asthma was 
high-intensity WTC exposure, and for isolated-COPD, it was ever-smoking. 
Post-9/11 accelerated FEV1 decline was associated with all three outcomes. 
The observed associations did not change when eosinophil concentration was 
assessed as a continuous variable (data not shown). 
 
To confirm that elevated post-9/11 eosinophil concentration and accelerated 
FEV1 decline were associated with incident asthma/COPD overlap, a 
sensitivity analysis was conducted excluding patients with a pre-exposure PFT 
that showed a FEV1/FVC ratio < 0.7 (N = 69). First post-9/11 eosinophil 
concentration ≥ 300 cells/µL and accelerated FEV1 decline both remained 
significant predictors of asthma/COPD overlap (HR, 1.67 [95% CI from 1.03 
to 2.71], P = 0.03; and HR, 2.15 [95% CI from 1.35 to 3.43], P = 0.001, 
respectively). To assess if pre-exposure blood eosinophil levels were 
indicative of a predisposition to asthma/COPD overlap, another sensitivity 
analysis was performed by using pre-9/11 eosinophil concentration in place 
of the post-9/11 measurement. The subgroup of participants who had had a 
pre-9/11 blood draw (N = 1 008) had baseline characteristics and lung function 
similar to those of the full study population (data not shown). We found that 
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pre-9/11 eosinophil concentration ≥ 300 cells/µL was also associated with the 
outcome (HR, 1.42; 95% CI from 1.22 to 1.66; P < 0.001). Change in 
eosinophil concentration from pre-9/11 to post-9/11 was not associated with 
asthma/COPD overlap (data not shown). 
 
To gain further insight into the immunologic pathways associated with 
isolated-asthma, isolated-COPD, and asthma/COPD overlap, we examined 
serum T-helper cell type 1, T-helper cell type 17 (Th17), and T-helper cell type 
2 (Th2) biomarkers obtained within 6 months of 9/11. A multivariable 
marginal Cox regression analysis for multiple events in the serum biomarker 
subpopulation (N = 215) found that higher early post-9/11 IgE was associated 
with incident asthma/COPD overlap, but this result was not significant after 
adjustment for multiple comparisons (Table 7). We found that elevated IL-4 
predicted asthma/COPD overlap and elevated IL-21 predicted both isolated-
asthma and isolated-COPD; elevated IFN-γ was a protective factor for 
isolated-asthma and isolated-COPD. Early post-9/11 levels of IL-5, IL-13, IL-
17, IL-23, and IL-6 were not associated with any of the three mutually 









Table 5 – Marginal Cox regression models predicting isolated-asthma, isolated-























≥ 300 cell / µLa 1.85 
1.16 – 
2.95 0.009 0.93 
0.63 – 





2.17 1.40 – 3.35 < 0.001 2.12 
1.54 – 
2.91 < 0.001 2.18 
1.59 – 
2.99 < 0.001 
Ever-smoker 0.92 0.58 – 1.44 0.70 0.77 
0.56 – 




morning of 9/11 1.40 
0.84 – 
2.32 1.58 1.58 
1.14 – 
2.20 0.006 0.86 
0.59 – 
1.26 0.44 
The total N value was 2 124 due to missing covariates. Data were adjusted for age, race, BMI, and first 
post-9/11 FEV1/FVC measurement. 
aFirst post-9/11 measurement 
 
 
Table 6 – Marginal Cox regression models predicting isolated-asthma, isolated-






HR 95% CI 
P 




≥ 300 cell / µLa 2.00 
1.11 –  
3.62 0.02 1.60 




1.02 0.60 –  1.74 0.94 0.99 
0.60 –  
1.65 0.98 
Ever-smoker 1.19 
0.69 –  
2.05 0.52 0.57 
0.34 –  
0.98 0.04 
WTC exposure morning of 9/11 0.88 0.49 –  1.61 0.68 1.62 
0.88 –  
3.01 0.12 
The total N value was 2 124 due to missing covariates. Data were adjusted for age, race, BMI, and first 
post-9/11 FEV1/FVC measurement. 
aFirst post-9/11 measurement 
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Table 7 – Marginal Cox regression models predicting isolated-asthma, isolated-
COPD, and asthma/COPD overlap in the subpopulation with serum drawn between 





















IgE a 2.31 1.14 – 4.67 0.02






b 0.48 0.32 – 0.70 < 0.001 0.45 
0.28 – 
0.70 < 0.001 
IL-21a 1.33 0.89 – 1.98 0.17 1.73 
1.27 – 
2.35 < 0.001 2.06 
1.31 – 
3.23 0.002 
IL-4 substituted for 
IL-21 in marginal  
Cox regression model 
IL-4a 1.51 1.17 – 1.95 0.002 1.68 
1.08 – 
2.61 0.02
b 1.35 0.96 – 1.91 0.08 
The total N value was 215. Data were adjusted for age, race, BMI, smoking status, WTC exposure level, 
and first post-9/11 FEV1/FVC measurement. 
aOne log2 increase (doubling) of cytokine concentration. 











Figure 16 – Cumulative incidence of asthma/COPD overlap in WTC-exposed 
firefighters who had a BD PFT. (A) Cumulative incidence of asthma/COPD 
overlap in participants with blood EOS concentration ≥ 300 cells/µL (orange) and 
< 300 cells/µL on first post-9/11 medical monitoring examination (green). The 
level of significance shown in each panel was determined by using the log-rank 
test. (B) Cumulative incidence in those who reported ever smoking (orange) and 
never smoking (green). (C) Cumulative incidence in participants who had an 
accelerated rate of post-9/11 FEV1 decline > 64 mL/y (orange) and those with 
expected FEV1 decline ≤ 64 mL/y (green). 
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III.2.4. Discussion & Conclusion 
 
The WTC-exposed FDNY firefighter population is a cohort comprising 
previously healthy male subjects. Importantly, asthma documented during 
preemployment medical evaluation precludes employment as a FDNY 
firefighter. Those who develop reactive airways disease during their career are 
removed from active duty[131]; therefore, the prevalence of pre-9/11 asthma 
in this cohort was low. The massive irritant exposure at the WTC site resulted 
in an acute drop in lung function, with rescue/recovery workers going on to 
experience air trapping, as well as fixed and reversible airflow 
obstruction.[29,44,45] In the present study, we observed that elevated early 
post-9/11 blood eosinophil concentration predicted irritant-associated 
asthma/COPD overlap but not isolated-asthma or isolated-COPD. A 
sensitivity analysis noted that pre-9/11 elevated eosinophils were a risk factor 
for asthma/COPD overlap. This finding suggests a pre-WTC exposure 
predisposition to irritant-associated fixed and reversible airway injury. 
Although we found some overlapping biomarkers of these outcomes, the 
observation that there are unique biomarkers of vulnerability to asthma/COPD 
overlap, isolated-asthma, and isolated-COPD suggests the potential for 
different pathologic processes for these three diagnoses; this topic could be 
explored in future studies. 
 
The FDNY WTC-exposed cohort has advantages for investigating irritant-
associated airways disease. Data from a centralized post-WTC medical 
treatment program enabled explicit diagnostic criteria for incident isolated-
asthma, isolated-COPD, and asthma/COPD overlap. Pre-9/11 lung function 
and blood data were available for a large subset of the cohort, enabling 
assessment of early indicators of susceptibility to subsequent airway injury. 
Our observation that pre-exposure eosinophil concentration was associated 
with later asthma/COPD overlap suggests patient-intrinsic vulnerability to the 
damaging effects of WTC dust exposure. How much the exposure itself 
contributed to the presentation is limited because not every assessment was 
performed pre-exposure. 
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Compared with those who developed isolated-asthma or isolated-COPD, 
patients with asthma/COPD overlap had a lower post-exposure FEV1 and 
FEV1/FVC ratio. An investigation in a cohort without WTC exposure found 
that low lung function in childhood was a risk factor for subsequent 
asthma/COPD overlap,[132] and thus our observed associations between early 
lung function measurements and this outcome may be evidence of similar 
biological mechanism(s). Both the asthma/COPD overlap, and isolated-COPD 
subgroups have progressive airway injury, with greater post-9/11 FEV1 rates 
of decline than individuals with isolated-asthma or neither diagnosis. The 
asthma/COPD overlap subgroup also experienced more air trapping, shown 
by higher RV/TLC at the time of BD-PFT. This finding is consistent with 
previous investigation of asthma/COPD overlap in never-smokers[133] and 
could be evidence of the severity of small airways dysfunction associated with 
WTC exposure.[134] 
 
Eosinophils and IgE are two Th2 mediators that have been extensively studied 
as risk factors for asthma, COPD, and asthma/COPD overlap.[126,135–139] 
In the present investigation, serum IgE was associated with asthma/COPD 
overlap but did not achieve significance after Bonferroni adjustment for 
multiple comparisons. We did observe a significant association between 
serum levels of the Th2 cytokine IL-4 and this outcome. IL-4 may be a 
biomarker on the causal pathway to irritant-associated asthma/COPD overlap 
because inhibiting it with dupilumab reduced asthma severity in non-WTC-
exposed patients with or without high eosinophil levels.[140,141] Further 
investigation is required to assess the Th2 pathways that are associated with 
FEV1 decline, airflow limitation, and BD response following an intense 
irritant exposure. 
The incident asthma observed in the present study is a variant of irritant-
induced asthma.[142] The fact that it was associated with high-intensity WTC 
exposure but not eosinophil concentration suggests that airway reactivity in 
this cohort is a form of non-eosinophilic asthma.[143] IFN-γ was a protective 
biomarker for this condition and also for isolated-COPD. High IFN-γ is 
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associated with low IL-4 in modulation of pulmonary lymphocyte-mediated 
innate immunity.[144] Furthermore, asthma is associated with blunted IFN-g 
response.[145,146] 
 
The balance between Th2 and Th17 cytokines in airway inflammation is under 
active investigation.[147–149] IL-21, which was found to significantly predict 
isolated-asthma and isolated-COPD in the present cohort, is a component of 
the Th17 pathway that is produced by innate lymphoid cells which regulate 
airway inflammation.[150] Elevated levels are associated with airway 
inflammation in mouse models and humans.[151–153] The data from the 
WTC-exposed FDNY cohort are consistent with a Th2 and Th17 response 
predicting 
airway remodeling and reactivity. These data support further investigation of 
the innate Th17 response to pulmonary irritants. 
 
In univariable analyses, we found that in addition to high eosinophil 
concentration and accelerated FEV1 decline, ever-smoking was associated 
with asthma/COPD overlap. After adjusting for confounders, such as post-
9/11 lung function, smoking was a unique risk factor for isolated-COPD but 
not isolated-asthma or asthma/COPD overlap. Therefore, the relationship 
between smoking and asthma/COPD overlap in this cohort was confounded 
by the other covariates. High WTC exposure level was not associated with 
isolated-COPD or asthma/COPD overlap, which suggests that an intense but 
brief irritant exposure did not increase risk of airway remodeling. In this 
cohort, isolated-COPD was not associated with eosinophil levels. In a 
population with smoking-related COPD, however, elevated blood eosinophil 
concentration was a biomarker of increased exacerbation.[154] The variability 
of eosinophil effect reported in the literature may be related to the proportion 
of the study cohorts with an asthma component.[155,156] 
 
There are several limitations to this investigation. The FDNY firefighters are 
overwhelmingly white, male, and experienced a massive irritant exposure, 
potentially limiting generalizability of these findings; however, most findings 
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from the FDNY cohort have been replicated in other WTC-exposed cohorts. 
Our definitions of isolated asthma, asthma/COPD overlap, and isolated COPD 
depend on results from the most recent BD-PFT. It is possible that those with 
isolated COPD, defined as FEV1/FVC < 0.7 and no BD response in this study, 
have asthma/COPD overlap because we did not proceed to methacholine 
challenge testing in the subgroup. Similarly, those with asthma/COPD 
overlap, defined as FEV1/FVC < 0.7 and a BD response, may not have 
persistent FEV1/FVC < 0.7 with permanent airway remodeling. A third 
limitation may be the use of eosinophils ≥ 300 cells/µL or < 300 cells/µL in 
our analyses. We modeled post-9/11 eosinophils as a continuous variable and 
still observed a significant association with asthma/COPD overlap. This 
method suggests that cut-point selection did not drive the analyses. Lastly, this 
study was vulnerable to selection bias. The study population with clinically 
indicated BDPFT was systematically different from those without BDPFT, 
with more intense WTC exposure, higher eosinophil levels, and post-WTC 
exposure lower lung function. This outcome precludes assessment of rates of 
asthma/COPD overlap in the entire cohort because undiagnosed cases are 
likely. Nevertheless, analyses within the BD-PFT population provide a valid 
assessment of risk factors for specific diagnoses within a symptomatic 
subgroup. 
 
In conclusion, the data from the FDNY WTC Health Program are a valuable 
resource for understanding irritant-associated airways disease in a previously 
healthy population. High eosinophil concentrations, uniquely associated with 
asthma/COPD overlap in this population, may reflect biological pathways that 
predispose one to exaggerated inflammation and/or poor counterregulatory 
responses to inflammation, leading to reversible and fixed airflow obstruction. 
There may be potential for early interventions that involve targeting specific 
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Berger KI, Nolan A, Prezant DJ, Weiden MD. Predictors of Asthma/COPD 
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III.3. Low serum IgA and airway injury 
III.3.1. Introduction 
 
The collapse of the World Trade Center (WTC) exposed rescue/recovery 
workers to an intense dust cloud, causing airway inflammation and subsequent 
accelerated decline in FEV1.[157] Accelerated FEV1 decline is a risk factor 
for fixed and variable airflow obstruction.[116] IgA protects airways from 
immunological, infectious or toxic injury. Serum IgA ≤ 70 mg/dL increases 
risk for acute exacerbations of chronic obstructive pulmonary disease (COPD) 
treated with antibiotics.[158] Secretory IgA is reduced in those with damaged 
airways.[159,160] We aimed to determine if reduced serum IgA ≤ 70 mg/dL 
soon after WTC exposure was associated with subsequent airway injury, 
defined by worse lung function and increased antibiotic treatment. 
III.3.2. Methods 
III.3.2.1. Clinical Data 
The source population contained 9 638 WTC-exposed male FDNY 
firefighters (Figure 17). The study population consisted of 917 firefighters 
with baseline serum drawn between October 2001 and March 2002 and 
immunoglobulin concentrations (including IgA) assayed with HGAMMAG-
301K (EMD Millipore). Antibiotic and oral steroid courses per person, at least 
6 weeks apart, were obtained from a billing database initiated on 1 January 
2007. Three persons were lost to follow-up before 2007 and excluded from 
the medication analyses. Spirometric measurements were collected during 
routine medical monitoring examinations between 11 September 2000 and 10 
September 2018. Clinically indicated bronchodilator pulmonary function tests 
(BD-PFTs) were performed on a subpopulation of 284 individuals between 
February 2002 and August 2018. FDNY databases contributed demographic 
and smoking status data. 
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Figure 17 – Flow diagram of study population 
 
III.3.2.2. Statistical Analysis 
Longitudinal FEV1 and rates of FEV1 decline were estimated in the 
IgA ≤ 70 mg/dL and IgA > 70 mg/dL subgroups using random intercept linear 
mixed-effects models. Participants’ age on 11 September 2001, height and 
race were included as fixed effects in the models for FEV1 absolute and FEV1 
decline. Mean ± SEM FEV1 and FEV1 % predicted were estimated for each 
1–year period between 11 September 2000 and 10 September 2018. 
Multivariable Cox regression assessed the association between IgA and fixed 
airflow obstruction characteristic of COPD (post-BD FEV1/FVC < 0.70) on 
the last BD-PFT. Follow-up time started 11 September 2001 and ended at the 
last BD-PFT. Multivariable Poisson models compared rates of antibiotic 
courses in IgA ≤ 70 mg/dL and IgA > 70 mg/dL subgroups.  
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To avoid immortal time bias, follow-up time for medication use started 1 
January 2007 and ended at the latest of the following dates for retirees: last 
medication prescription date or last medical exam; and on 10 September 2018 
for active firefighters. All models were adjusted for age on 9/11, race, body 
mass index, smoking status and WTC exposure. Covariates were selected 
based on theory. Data analyses were performed using SAS V.9.4 and figures 
created using Prism V.8. 
III.3.3. Results 
III.3.3.1. Demographics 
The study population was slightly older (41.4 ± 7.4 vs 40.1 ± 7.4 years) and 
had fewer ever-smokers (16% vs 35%) than the firefighters without IgA 
measured (Table 8). IgA ≤ 70 mg/dL (low IgA) was present in 9% of the study 
population (83/917), but the proportion of IgA measurements ≤ 70 mg/dL was 
highest in those with measurements closest to 9/11 (Figure 18). The low-IgA 
subgroup had similar levels of IgE and IgM as the IgA > 70 mg/dL group, but 
lower levels of certain IgG concentrations (Table 9). 
III.3.3.2. Early IgA and lung function 
The low-IgA subgroup had lower FEV1 % predicted and absolute FEV1 than 
the IgA > 70 mg/dL subgroup before 9/11 and throughout follow-up (Figure 
19 and Figure 20). Pre-9/11 FEV1 % predicted in those with low IgA was 
102.8% (95%CI 99.3% to 106.4%) vs 106.0% (95%CI 105.0 to 107.0) in those 
with IgA >70 mg/dl; first post-9/11 FEV1 % predicted was 94.1% (95% CI 
90.7 to 97.4) compared with 98.6% (95% CI 97.7% to 99.5%) and last FEV1 
% predicted was 88.6% (95% CI 85.1% to 92.1%) compared with 94.0% (95% 
CI 93.0% to 95.0%). The subgroups had similar post-9/11 FEV1 slopes (Figure 
20 and Table 9). Low IgA increased the risk of postbronchodilator FEV1/FVC 
<0.70 by 3.8-fold (95% CI 1.6 to 8.8) (Table 10). 
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Table 8 – Baseline characteristics and longitudinal FEV1 
Variable 
No serum IgA 
measured 
N = 8 721 
IgA study 
population 
N = 917 
Bronchodilator 
PFT with IgA 
N = 284 
Age on 9/11, y a,b 40.1 ± 7.4 41.4 ± 7.4 41.0 ± 6.5 
BMI, kg/m2 b 28.9 ± 3.4 28.5 ± 3.2 28.6 ± 3.3 
    
Smoking status, n (%) 
Never 5 687 (65.2) 770 (84.0) 250 (88.0) 
Ever 3 034(34.8) 147 (16.0) 34 (12.0) 
    
Race, n (%)    
White 8 201 (94.0) 878 (95.8) 277 (97.5) 
Black 210 (2.4) 15 (1.6) 4 (1.4) 
Hispanic 285 (3.3) 23 (2.5) 3 (1.1) 
Other 25 (0.3) 1 (0.1) 0 
    
WTC arrival time, n (%) c 
Morning of 9/11 1 428 (16.4) 148 (16.1) 48 (16.9) 
Afternoon on 9/11 or 
12/9/2001 
6 199 (71.1) 707 (77.1) 224 (78.9) 
13/9 - 24/9/2001 1094 (12.5) 62 (6.8) 12 (4.2) 
    
Spirometry    
FEV1 (l) b,c 4.00 ± 0.67 4.06 ± 0.70 3.96 ± 0.71 
FEV1 % predicted b,c 96.9 ±13.6 98.2 ± 14.6 94.9 ± 15.0 
FEV1 slope ml/y b -36.3 ± 27.7 -38.9 ± 29.8 -41.2± 35.5 
 
 
a11 September 2001  
bMean ± standard deviation     
cValue on first post-9/11 monitoring exam 
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Table 9 – Baseline characteristics and longitudinal FEV1 by IgA subgroups 
Variable 
IgA > 70 mg/dl 
N = 834 
IgA ≤ 70 mg/dl 
N = 83 
Age on 9/11, y a,b 41.5 ± 7.5 40.8 ± 6.7 
BMI, kg/m2 b 28.5 ± 3.2 28.8 ± 3.4 
   
Smoking status, n (%)   
Never 703 (84) 69 (83) 
Ever 131 (16) 14 (17) 
   
Race, n (%)   
White 793 (95) 79 (96) 
Black 19 (2.2) 1 (1.1) 
Hispanic 21 (2.5) 3 (3.3) 
Other 1 (0.1) 0 
   
WTC arrival time, n (%)   
Morning of 9/11 135 (16) 17 (21) 
Afternoon on 9/11 or 
12/9/2001 
636 (76) 63 (77) 
13/9 - 24/9/2001 62 (7.5) 2 (2.2) 
   
Spirometry   
FEV1 (L) b,c 4.05 ± 0.67 3.89 ± 0.65 
FEV1 % predicted b,c 98.2 ±13.5 94.1 ± 15.4 
FEV1 slope ml/y b -38.4 ± 34.0 -38.5 ± 37.2 
   
Serum immunoglobulin mg/dl 
IgE 0.51 ± 0.73 0.46 ± 0.51 
IgM 143 ± 83 143 ± 200 
IgG1 466 ± 213 383 ± 191 
IgG2 329 ± 183 251 ± 184 
IgG3 208 ± 375 86 ± 76 
IgG4 103 ± 265 64 ± 46 
 
 
a11 September 2001   
bMean ± standard deviation   
cValue on first post-9/11 monitoring exam 
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Figure 18 – Low serum IgA over time. The proportion of IgA measurements that 
were ≤70mg/dl (low IgA) is shown in each of 4 time intervals post-WTC exposure: 
1-2 months, 2 to 2.5 months, 2.5 to 3.5 months and 3.5-6 months. The proportion 
of individuals with low IgA declined as time post-WTC exposure increased (p < 
0.001Chi-square trend). Mean and SEM are shown. 
 
III.3.3.3. Early IgA and antibiotic treatment 
After 1 January 2007, the rate of antibiotic use was 22.5 antibiotic 
courses / 100 person-years in those with low IgA, compared with 11.6 
antibiotic courses / 100 person-years in those with IgA > 70 mg/dl (unadjusted 
p=0.002). The low-IgA subgroup had a 1.9-fold increased rate of antibiotic 
treatment (95% CI 1.2 to 2.9) in multivariable Poisson regression, adjusted for 
potential confounders (Table 11). Oral steroid use, however, was not 
significantly associated with IgA level (Table 12). 
 
Table 10 – Multivaraible Cox model examining the association between serum 
IgA ≤ 70 mg/dl and postbronchodilator FEV1/FVC ratio less than 0.70 a,b 
Variable HR 95% CI P value 
IgA ≤ 70 mg/dl 3.75 1.59 to 8.83 0.0025 
Age 1.10 1.04 to 1.16 0.0008 
Ever smoker 4.58 2.06 to 10.20 0.0002 
 
aTime from 11 September 2001 to BD-PFT, median (IQR): 5.9 years (3.6–9.9). 
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bN = 284; also adjusted for race, WTC exposure and BMI. 
 
Table 11 – Multivariate Poisson model examining the association between serum 
IgA ≤ 70 mg/dl and courses of antibiotic treatment after 1 January 2007 c 
Variable HR 95% CI P value 
IgA ≤ 70 mg/dl 1.90 1.24 to 2.90 0.003 
Age 0.99 0.97 to 1.02 0.63 
Ever smoker 0.68 0.41 to 1.12 0.13 
 
cN = 914; also adjusted for race, WTC exposure and BMI.  
 
Table 12 – Multivariate Poisson model examining the association between serum 
IgA ≤ 70 mg/dl and courses of oral steroid treatment d  
Variable HR 95% CI P value 
IgA ≤ 70 mg/dl 1.47 0.78 to 2.75 0.23 
Age 0.99 0.96 to 1.02 0.64 
Ever smoker 0.52 0.24 to 1.10 0.09 
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Figure 19 – Lung function over time stratified by IgA measured on 11 September 
2001 to 10 March 2002. The mean (±SEM) FEV1 % predicted is shown in each 
year between 11 September 2000 and 10 September 2018. The triangles 
correspond to the IgA ≤70 mg/dL subgroup (N = 83). Dots correspond to the IgA 
>70 mg/dL subgroup (n=834). The number of spirometric measurements in each 
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Figure 20 – Lung function over time stratified by IgA measured on 11 September 
2001 to 10 March 2002. The mean absolute FEV1 is shown in the groups with 
higher resp. lower than 70 mg/dL IgA in each year, adjusted for age, race and 
height, using the same spirometry measurements as in Figure 19. 
 
 
Page 74  
III.3.4. Discussion & Conclusion 
 
In an occupational cohort with low smoking prevalence and preserved lung 
function, low IgA (IgA ≤ 70 mg/dl) soon after an intense irritant exposure was 
associated with lower FEV1 measurements throughout longitudinal follow-up 
and increased antibiotic treatment. Low IgA was also associated with 
development of fixed airflow obstruction. These data build on recent reports 
demonstrating that low IgA is a risk factor for COPD exacerbation and airway 
injury in current and former smokers with reduced lung function.[158,159] 
 
Low IgA was observed as part of an intense, but transient inflammatory 
response to inhaled particulates. This may account for the high prevalence of 
low IgA in this cohort when compared with the SPIROMICS cohort.[158] 
These observations are consistent with suppression of production of IgA or 
increased degradation of IgA by proteases such as neutrophil elastase.[161] 
Local IgA deficiency has been associated with smoking-related COPD and 
increased susceptibility to smoking-related lung injury.[161] Low IgA soon 
after irritant exposure may serve as a proxy for increased susceptibility to lung 
injury. 
 
There are several limitations to this study. This study employed an arbitrary 
cut point to define low IgA, although one consistent with prior literature.[158] 
Nevertheless, the results support the conclusion that 70 mg/dl represents a 
reproducible threshold for outcomes relevant to lung injury. The unusual 
nature of the massive irritant exposure that produced lung injury in this cohort 
could limit generalizability of these data, although our findings are consistent 
with other observations in smoking-related lung injury. Finally, since this was 
an observational study, it may be subject to unmeasured confounding and 
selection bias. 
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IgA ≤ 70 mg/dl in the first 6 months post-9/11 predicted antibiotic use years 
later. Since IgA was measured shortly after 9/11 and prior to disease 
presentation, it is unlikely that low IgA is a consequence of abnormal lung 
function. Since reduced FEV1 in the low-IgA subgroup was persistent 
throughout follow-up, including before 9/11, this suggests that recurrent 
infection could have impacted lung function during development and/or 
adulthood.[162,163] Since low maximally-attained FEV1 is a risk factor for 
obstructive lung disease, even in individuals with expected FEV1 
decline,[164] further research should test if IgA levels are associated with 
maximally attained FEV1 and fixed airflow obstruction in other populations. 
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III.4. Factors predicting treatment of World Trade Center-




Rescue and recovery workers suffered a massive exposure to dust and 
products of combustion after the collapse of the WTC twin towers.[165] This 
resulted in increased rates of respiratory symptoms, as well as an acute drop 
of lung function and subsequent high incidence of reactive airways disease 
and fixed airflow obstruction.[116,117,157,166–169] Immediately after 11 
September 2001 (9/11), the FDNY instituted a medical monitoring program 
that performed screening pulmonary function tests and collected respiratory 
symptom data via computer-based questionnaires.[170] Additionally, FDNY 
began a treatment program at no cost to the participants. Longitudinal data 
from these monitoring and treatment programs have identified WTC-related 
diseases and treatment responses. We previously found that initiation of 
treatment with inhaled steroids combined with long-acting beta agonists 
(ICS/LABA) sooner after WTC exposure was more likely to result in 
improvement of dyspnea in the FDNY cohort than initiation of treatment years 
after WTC exposure.[171]  
 
ICS/LABA is the standard of care for asthma and COPD with 
exacerbations.[111,112] Current guidelines on obstructive airway diseases 
recommend that physicians evaluate lung function, respiratory symptoms, and 
frequency of exacerbations to inform treatment strategies.[172,173] In the era 
of telemedicine, web-based symptom monitoring, wearable devices, and data 
transmission technology are becoming more widely used.[174,175] Predictive 
models using these data will help detect individuals with undiagnosed disease 
who may benefit from early interventions such as subspecialty testing and 
treatment. 
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It remains unclear which factors identify at-risk individuals prior to the 
development of abnormal lung function on screening spirometry exams. A 
subgroup of individuals has experienced an accelerated decline of lung 
function, but the majority still have spirometry measurements within normal 
limits.[157] The objective of this study was therefore to identify patient 
characteristics collected on routine medical monitoring that would predict 
WTC-related lung injury defined by initiation of ICS/LABA treatment for 
more than 2 years. 
 
III.4.2. Materials and Methods 
III.4.2.1. Source population and data sources 
The source population included 10 168 World Trade Center (WTC)-exposed 
male firefighters who were actively employed by FDNY on 11 September 
2001, consented to research, and had at least one routine medical monitoring 
exam between 11 September 2001 and 1 July 2018 (Figure 21). Since the 
FDNY WTC-exposed firefighter cohort was less than 1% female, women 
were not included from the source population into our study. 
 
Data on demographics, height, weight, smoking status, WTC exposure level 
(defined by initial arrival time to work at the WTC site), spirometry 
measurements, and respiratory symptoms were retrieved from the FDNY 
employee database (race, sex, and age) or were assessed during routine 
medical monitoring exams. Spirometry measurements included FEV1 and 
FEV1/FVC ratio. Respiratory symptoms included self-reported wheeze, 
dyspnea, and provocability. Provocability was evaluated by asking about 
symptoms of cough, wheeze, dyspnea, or chest tightness when exposed to 
smoke, fumes, odors, dust, allergens, temperature or humidity extremes, or 
physical activity. When individuals reported at least one respiratory symptom 
of provocability on the medical monitoring questionnaire, they were 
considered as having provocability. 
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Figure 21 – Flowchart of the study population. The source population included 
10 168 World Trade Center (WTC)-exposed male firefighters who were actively 
employed by FDNY on 11 September 2001, consented to research, and had at least 
one routine medical monitoring exam between 11 September 2001 and 1 July 2018. 
After applying exclusion criteria for individuals missing a spirometry in the 
initiation interval or having inhaled corticosteroid/long-acting beta-agonist 
(ICS/LABA) initiation before first monitoring date, the analytic population 
included 9 247 firefighters. Excluding individuals who initiated ICS/LABA for 
≤ 2 years, a study population of 8 530 firefighters was established to perform the 
main analyses. 
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III.4.2.2. ICS/LABA treatment 
Medication data were obtained from the FDNY electronic medical record 
(EMR) and the FDNY WTC health program claims database. The date of 
treatment initiation was defined as the earliest of either the first note in the 
EMR or the first prescription billed. Treatment duration was defined as the 
interval between first and most recent prescription fill dates of ICS/LABA. 
Individuals were considered as having been treated with ICS/LABA therapy 
when the duration was at least 2 years (N = 2 162). 
 
III.4.2.3. Dataset structure and exclusions 
Analytic datasets were organized into 2-year time intervals, starting 11 
September 2001 and ending 1 July 2018. When multiple visits occurred in the 
same 2-year time interval, the first visit with available data was used. 
Individuals missing a spirometry measurement in their ICS/LABA initiation 
interval (N = 813) were excluded from the analyses. As shown in Figure 21, 
an additional 108 individuals who had an ICS/LABA initiation date before 
their first monitoring exam date were also excluded. After applying those 
exclusion criteria, the analytic population included 9 247 firefighters. 
Additionally, 717 individuals who initiated ICS/LABA for ≤ 2 years were 
excluded (Figure 21). Among the remaining study population of 8530 
firefighters, 1 629 individuals initiated ICS/LABA for > 2 years between 11 
September 2001–1 July 2018. During the subsequent intervals, individuals 
missing spirometry data on a particular visit were excluded from that interval 
(total of 1 496 visits). The follow-up time ended at either date of ICS/LABA 
initiation, participants’ last monitoring exam (if retired), or the end of the 
study period (1 July 2018), whichever came first. Missing respiratory 
symptom data were imputed by using symptom data from the prior interval. 
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III.4.2.4. Statistical analysis 
Descriptive statistics were reported as proportions for categorical variables 
and means (with SD) for continuous variables, all of which met normality 
assumptions. Differences between groups were evaluated by chi-squared and 
t-tests, respectively. 
 
Multinomial logistic model assessed the associations of the number of 
respiratory symptoms of wheeze, dyspnea, or provocability with ICS/LABA 
treatment (> 2y, ≤ 2y vs. no ICS/LABA) as the outcome. The four-level 
symptom variable compared those that had one, two, or three respiratory 
symptoms versus none of those three. The models were adjusted for age, WTC 
exposure, retirement status and FEV1. Multivariable logistic regression was 
used to determine covariates associated with initiation of ICS/LABA 
treatment versus no ICS/LABA treatment, for each 2-year interval. 
Individuals who had already been prescribed ICS/LABA treatment were 
excluded from the analyses of the later intervals. We performed receiver 
operating characteristic (ROC) analysis for the logistic models, calculating the 
area under the curve (AUC). The covariates were chosen based on theory and 
different models were evaluated using the AUC of the model.  
 
Cox proportional hazards regression was used to assess the validity of the 
probability of ICS/LABA initiation generated by the earlier logistic models to 
predict future ICS/LABA initiation. The upper 10th percentile of the 
probability from a 2-year interval was used as the exposure variable. The 
follow-up time started the beginning of the intervals tested (2007 and 2015, 
respectively) and ended at the earliest actual ICS/LABA initiation, last 
monitoring exam, or the end of the intervals tested (11 September 2011 or 1 
July 2018), whichever came first. We tested the proportional hazard 
assumption and all models met the assumption. 
 
In a sensitivity analysis, we used only complete data available for the logistic 
models, without imputing missing data for respiratory symptoms from the 
prior interval (N = 8 466). 
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In a second sensitivity analysis we included individuals that had ICS/LABA 
treatment for less than 2 years (N = 717 after exclusions) in the ICS/LABA 
treatment group (total N = 9 247). 
 
Data analyses were performed using SAS 9.4 (SAS Institute Inc. Cary, NC). 
Figures were made using SAS and R v3.6.0.2 (R Core Team. R: A Language 




III.4.3.1. ICS/LABA use in population 
During the study period, 6 901 individuals never initiated ICS/LABA and 
1 629 received ICS/LABA treatment for more than 2 years. The median 
treatment duration of this treated group was 8.5 years (IQR 5.0–12.5). The 
proportion of individuals that was persistent in ICS/LABA use > 2 years out 
of all ICS/LABA initiators was 1 629/2 346 (69.4%). 
 
The number of individuals who initiated ICS/LABA in each 2-year time 
interval ranged between 34 and 292 (median 184 IQR 205–163) (Figure 22). 
The mean FEV1 around the time of ICS/LABA initiation was 87.7 ± 14.1% 
predicted and the FEV1/FVC ratio was 0.78 ± 0.07. Compared with nontreated 
individuals, a greater proportion of individuals who received ICS/LABA for 
more than 2 years arrived at the WTC site on the morning of 9/11 (19.5% vs. 
15.0%) (Table 13). The 717 WTC exposed firefighters who were treated with 
ICS/LABA for ≤ 2 years had intermediate WTC exposure intensity, with 
17.9% of treated individuals arriving on morning of 9/11. 
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Figure 22 – Distribution of individuals initiating ICS/LABA for more than 2 years 
(N = 1 629) per time interval. The first interval, 11 September 2001 – 10 September 
2003, with 292 individuals starting ICS/LABA treatment, had the highest number. 
In the other, full 2-year intervals the numbers of individuals initiating ranged from 
139 to 239 per 2-year time interval. The last interval 11 September 2017 – 1 July 
2018, which was not a full 2-year interval (striped filling pattern), contained 34 
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N = 8 530 
ICS/LABA  
non-treated 
N = 6 910 
ICS/LABA  
treated > 2 y 
N = 1 629 
ICS/LABA 
treated ≤ 2 y 
N = 717 
Age on 9/11, y 40.5 ± 7.5 40.4 ± 7.7 40.8 ± 6.8 39.8 ± 7.3 
Height, cm 177.1 ± 6.4 177.0 ± 6.4 177.2 ± 6.6 177.5 ± 6.6 
Smoker, ever a 2 195 (25.7) 1 754 (25.4) 441 (27.1) 199 (27.8) 
     
Race, n (%)     
White 8 008 (93.9) 6 464 (93.7) b 1 544 (94.8) b 677 (94.4) 
Black 221 (2.6) 198 (2.9) b 23 (1.4) b 12 (1.7) 
Other 301 (3.5) 239 (3.5) b 62 (3.8) b 28 (3.9) 
     
WTC exposure level, n (%)    
Morning of 
9/11 1 352 (15.9) 1 034 (15.0) 
b 318 (19.5) b 128 (17.9) 
Afternoon on 
9/11 to 12 Sept 2001 6 065 (71.1) 4 908 (71.1) 
b 1 157 (71.0) b 524 (73.1) 
13 Sept to 
24 Sept 2001 1 113 (13.1) 959 (13.9) 
b 154 (9.5) b 65 (9.1) 
     
Baseline FEV1, L a 4.01 ± 0.68 4.06 ± 0.66 b 3.80 ± 0.68 b 3.97 ± 0.68 
Baseline FEV1 % 
predicted a 97.3 ± 13.6 98.6 ± 13.1 
b 91.8 ± 14.1 b 95.2 ± 14.2 
Baseline wheeze a 1 797 (21.1) 1 210 (17.6) b 587 (36.0) b 216 (30.2) 
Baseline dyspnea a 2 454 (28.9) 1 720 (25.0) b 734 (45.1) b 272 (38.0) 
aAt first post-9/11 exam 
bP < 0.01 on t-tests and chi-squared 
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III.4.3.2. Concurrent symptoms and ICS/LABA treatment duration 
We hypothesized that duration of treatment was associated with lung function 
and symptoms at the time of ICS/LABA initiation. To assess if patients with 
> 2 years of ICS/LABA treatment were different from those with ≤ 2 years of 
ICS/LABA treatment, we performed multinomial logistic regression. As 
shown in Table 14, smaller expiratory lung volumes (FEV1) were more 
strongly associated with > 2 years of ICS/LABA treatment than with ≤ 2 years 
of ICS/LABA treatment (OR 2.36 per L less, 95% CI 2.10–2.67 vs. 1.52, 95% 
CI 1.52–1.77). We also observed that concurrent symptoms were more 
strongly associated with > 2 years of ICS/LABA treatment than with ≤ 2 years 
of ICS/LABA treatment. Compared with an asymptomatic patient, a patient 
with symptoms of wheeze, dyspnea, and provocability was 28-fold more 
likely (95% CI 23.2–35,8) to be treated with ICS/LABA for > 2 years and 
10-fold more likely (95% CI 7.6–13.3) to be treated with ICS/LABA for 
≤ 2 years. 
 
Table 14 – Multinomial logistic regressiona for ICS/LABA treatment (N = 9 018)b 
Variable 
ICS/LABA Treated > 2y  
N = 1 570 b 
ICS/LABA Treated ≤ 2y  
N = 690 b 
OR 95% CI 
P 
Value OR 95% CI 
P 
Value 
FEV1 absolutec, per -1, L 2.36 2.10 2.67 <0.001 1.52 1.31 1.77 <0.001 
         
Respiratory symptomsd         
1 vs. 0 3.68 3.06 4.42 <0.001 2.57 2.07 3.20 <0.001 
2 vs. 0 10.04 8.37 12.05 <0.001 5.47 4.38 6.83 <0.001 
3 vs. 0 28.80 23.19 35.76 <0.001 10.06 7.60 13.32 <0.001 
aAdjusted for age, WTC exposure, and retirement status. 
bN = 228 were excluded from the analysis due to missing covariates. (142 in ICS/LABA nontreated, 59 in 
> 2y and 27 in ≤ 2y group). ICS/LABA nontreated (N = 6 759) as the reference group 
cOn medical monitoring exam closest to ICS/LABA initiation or most recent for non-ICS/LABA. 
dNumbers of (concurrent) symptoms of wheeze, dyspnea, and/or provocability 
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III.4.3.3. Initiation of prolonged ICS/LABA treatment over time 
After excluding the 717 individuals who were treated for ≤ 2 years and using 
patient characteristics measured on routine monitoring exams from each 
2-year time interval over 16 years, we tested if factors associated with 
prolonged ICS/LABA treatment changed over time. Multivariable logistic 
regression demonstrated that wheeze, dyspnea, and lower FEV1 were 
persistent and independent correlates of ICS/LABA treatment (Figure 23). 
Symptoms of provocability were associated with ICS/LABA treatment after 
11 September 2007. High-intensity WTC exposure, defined as arriving at the 
WTC site on the morning of 9/11, was associated with ICS/LABA treatment 
from 11 September 2001–10 September 2003 but not significantly thereafter. 
Age was not a meaningful predictor of treatment in any of the intervals (Table 
15). 






FEV1 (per -1L)Time interval
   9/11/2001−9/10/2003     
   9/11/2003−9/10/2005     
   9/11/2005−9/10/2007     
   9/11/2007−9/10/2009     
   9/11/2009−9/10/2011     
   9/11/2011−9/10/2013     
   9/11/2013−9/10/2015     










0.25 0.50 1.0 2.0 4.0 8.0
OR (95% CI)
WheezeTime interval
   9/11/2001−9/10/2003     
   9/11/2003−9/10/2005     
   9/11/2005−9/10/2007     
   9/11/2007−9/10/2009     
   9/11/2009−9/10/2011     
   9/11/2011−9/10/2013     
   9/11/2013−9/10/2015     










0.25 0.50 1.0 2.0 4.0 8.0
OR (95% CI)
DyspneaTime interval
   9/11/2001−9/10/2003     
   9/11/2003−9/10/2005     
   9/11/2005−9/10/2007     
   9/11/2007−9/10/2009     
   9/11/2009−9/10/2011     
   9/11/2011−9/10/2013     
   9/11/2013−9/10/2015     










0.25 0.50 1.0 2.0 4.0 8.0
OR (95% CI)
Provocability‡Time interval
   9/11/2001−9/10/2003     
   9/11/2003−9/10/2005     
   9/11/2005−9/10/2007     
   9/11/2007−9/10/2009     
   9/11/2009−9/10/2011     
   9/11/2011−9/10/2013     
   9/11/2013−9/10/2015     








0.25 0.50 1.0 2.0 4.0 8.0
OR (95% CI)
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Figure 23 - Forest plots showing variables associated with the initiation of inhaled 
corticosteroid/long-acting beta-agonist (ICS/LABA) treatment > 2 years between 
11 September 2001 and 10 September 2017 (N = 1 629) versus not initiating 
ICS/LABA treatment (N = 6 901), created from multivariable logistic regression 
models examining the associations between medical monitoring exam covariates 
and initiation of prolonged ICS/LABA treatment (odds ratios (diamonds) and 95% 
confidence intervals (bars)). The models were adjusted for age and retirement 
status. Respiratory symptoms, such as wheeze, dyspnea, provocability, and lower 
FEV1, consistently predicted the early onset of lung injury defined by ICS/LABA 
treatment. High-intensity Word Trade Center exposure, based on arrival time, was 
strongly associated with ICS/LABA initiation soon after exposure. ‡ missing first 
two intervals because provocability data was not collected; * WTC exposure based 





   9/11/2001−9/10/2003     
   9/11/2003−9/10/2005     
   9/11/2005−9/10/2007     
   9/11/2007−9/10/2009     
   9/11/2009−9/10/2011     
   9/11/2011−9/10/2013     
   9/11/2013−9/10/2015     










0.25 0.50 1.0 2.0 4.0 8.0
OR (95% CI)
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Table 15 - Results from multivariable logistic regression models examining the 
associations between medical monitoring exam covariates and initiation of inhaled 
corticosteroid/long-acting beta-agonist (ICS/LABA) treatment >2 years between 11 
September 2001 and 10 September 2017 (N = 1 629) versus not initiating ICS/LABA 
treatment (N = 6 901). 
Variable 

































Total N used in 




278 116 171 190 236 180 201 162 
         
FEV1 absolute, 
per -1L 2.50 4.67 4.20 2.41 2.16 2.78 2.08 3.01 
Wheeze 2.58 2.00 2.34 2.99 2.65 2.81 1.87 3.23 
Dyspnea 2.40 2.89 2.98 4.48 2.81 1.90 2.69 3.61 
Provocability na na (1.23) 1.77 2.61 2.64 3.19 2.94 
WTC exposure, 




(2.21) (0.92) (1.23) (0.98) (1.00) (1.39) (1.64) (0.53) 
Age (1.01) (0.98) (1.00) (0.99) (0.99) (0.98) (1.00) (0.99) 
Active statuse f (0.41) (0.87) (1.10) 1.54 1.91 3.11 4.74 
aOdds Ratio when P < 0.05; (Odds Ratio) when P > 0.05 
bdifferent intervals result from separate models 
cindividuals might be excluded from the analysis due to missing covariates 
dWTC exposure based on arrival at the WTC site: morning 9/11(early), afternoon 9/11 or 12 September 
2001 (intermediate) and 13 September 2001 or later (late) 
enot having retired in previous interval 
festimate is 0 since all individuals were active on 9/11 
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We assessed ROC curves resulting from the models of each 2-year time 
interval. The AUC from the logistic models ranged from 0.77 (95% CI 0.73–
0.80) to 0.85 (95% CI 0.81–0.88).  
We then tested if high probability of ICS/LABA treatment, based on the 
logistic regression model results, increased the hazard of ICS/LABA initiation 
in subsequent time intervals using Cox proportional hazards models (Table 
16). The upper 10th percentile of risk for ICS/LABA initiation during the 
period 11 September 2005–10 September 2007 increased actual ICS/LABA 
treatment in the next interval by 3.32-fold (95% CI 2.58–4.26; P < 0.001) and 
in the 11 September 2015–1 July 2018 interval by 2.13-fold (95% CI 
1.37-3.32; P ≤ 0.001). 
 
Table 16 – Cox regression models for ICS/LABA treatment 
Probabilitya on 
ICS/LABA treatment Predicting HR 95% CI P Value 
11 Sep 2005–10 Sep 2007 11 Sep 2007–10 Sep 2011 3.32 2.58 4.26 <0.001 
11 Sep 2005–10 Sep 2007 11 Sep 2015–1 July 2018 2.13 1.37 3.32 <0.001 
aTop 10th percentile of probability on ICS/LABA treatment 
 
 
III.4.3.4. Sensitivity analysis 
The results of the sensitivity analysis using only complete data for the logistic 
model (N = 8 466) were similar to the primary analyses (Table 17). 
 
A sensitivity analysis comparing individuals with ICS/LABA treatment of any 
duration (N = 2 346) with never-treated individuals (N = 6 901) demonstrated 
similar findings as the primary analyses (Table 18). 
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Table 17 – Results from first sensitivity analysis using only complete data, not 
imputing missing data for respiratory symptoms from the prior interval (N = 8 466). 
Multivariable logistic regression models examining the associations between medical 
monitoring exam covariates and initiation of inhaled corticosteroid/long-acting beta-
agonist (ICS/LABA) treatment >2 years between 11 September 2001 and 10 
September 2017 (N = 1 629) versus not initiating ICS/LABA treatment (N = 6 837). 
Variable 

































Total N used in 




278 0g 171 189 228 163 186 159 
         
FEV1 absolute, 
per -1L 2.50 - 4.21 2.46 2.06 2.77 1.99 2.95 
Wheeze 2.58 - 2.34 3.03 2.75 3.09 2.05 3.22 
Dyspnea 2.40 - 2.98 4.61 3.00 2.00 2.70 3.60 
Provocability na - (1.23) 1.72 2.48 2.80 3.11 3.08 
WTC exposure, 




(2.21) - (1.23) (0.96) (1.01) (1.47) 1.61 (0.51) 
Age (1.01) - (1.00) (0.99) (0.99) (0.98) (1.00) (0.99) 
Active statuse f (0.87) (1.07) 1.51 1.72 3.06 4.65 (0.87) 
aOdds Ratio when P < 0.05; (Odds Ratio) when P > 0.05 
bdifferent intervals result from separate models 
cindividuals might be excluded from the analysis due to missing covariates 
dWTC exposure based on arrival at the WTC site: morning 9/11(early), afternoon 9/11 or 12 September 
2001 (intermediate) and 13 September 2001 or later (late) 
enot having retired in previous interval 
festimate is 0 since all individuals were active on 9/11 
gno individuals who initiated ICS/LABA having complete data, thus no model possible 
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Table 18 – Results from second sensitivity analysis including individuals that had 
inhaled corticosteroid/long-acting beta-agonist (ICS/LABA) treatment for less than 2 
years (N = 717) to the ICS/LABA treatment group. Multivariable logistic regression 
models examining the associations between medical monitoring exam covariates and 
initiation of ICS/LABA treatment (N = 2 346) between 11 September 2001 and 10 
September 2017 versus not initiating ICS/LABA treatment (N = 6 901). 
Variable 

































Total N used in 




436 168 222 243 309 234 257 233 
         
FEV1 absolute, 
per -1L 2.15 2.89 3.20 2.76 1.80 2.20 1.78 2.46 
Wheeze 2.27 2.17 2.18 2.38 2.58 3.04 1.87 2.82 
Dyspnea 2.45 2.21 2.37 3.58 2.93 1.88 2.62 3.18 
Provocability na na (1.18) 1.87 1.98 2.14 2.49 2.41 
WTC exposure, 




(1.61) (0.93) (1.33) (1.13) (1.09) (1.39) (1.65) (0.67) 
Age 1.02 (1.01) (1.00) (0.98) (0.99) (0.98) (1.01) 0.97 
Active statuse f (0.32) (0.96) (1.01) 1.37 1.79 2.98 3.81 
aOdds Ratio when P < 0.05; (Odds Ratio) when P > 0.05 
bdifferent intervals result from separate models 
cindividuals might be excluded from the analysis due to missing covariates 
dWTC exposure based on arrival at the WTC site: morning 9/11(early), afternoon 9/11 or 12 September 
2001 (intermediate) and 13 September 2001 or later (late) 
enot having retired in previous interval 
festimate is 0 since all individuals were active on 9/11 
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III.4.4. Discussion & Conclusion 
 
This retrospective cohort study identified factors predicting prolonged 
ICS/LABA treatment among WTC-exposed firefighters who were previously 
healthy when appointed to FDNY. Using longitudinal data from routine 
medical monitoring exams, we observed that wheeze, dyspnea, provocability, 
and lower FEV1 were independent risk factors for the early onset of lung injury 
defined by prolonged ICS/LABA treatment in patients with normal FEV1. 
There was a multiplicative increase in risk when two and three of the above 
symptoms co-occurred. We also demonstrated that factors present early in 
longitudinal follow-up increased the hazard for treatment initiation years later, 
suggesting that individuals with disease may have remained undiagnosed and 
untreated for significant periods of time. The diagnosis of occult disease as 
soon as possible is important, because in this cohort, delayed treatment was 
associated with poorer symptom control.[171] 
 
Wheeze and dyspnea, and lower FEV1 consistently predicted ICS/LABA 
initiation. Other factors, such as arrival at the WTC site on the morning of its 
collapse, provocability, and retirement status, changed over time. Using 
change-point models, we previously observed that the association of WTC 
exposure and obstructive airways disease have become attenuated over 
time.[176] Our observation that WTC exposure more strongly predicted 
ICS/LABA initiation shortly after is consistent with our prior studies. 
 
The respiratory symptoms assessed in the study were derived from self-
administered questionnaires and FEV1 measured with a handheld spirometer. 
These simple screening tests could be adapted to a telemedicine format. The 
importance of lung function and respiratory symptoms was recently studied 
with peak expiratory flow and asthma symptom scores in home telemonitoring 
to predict asthma exacerbations using machine learning algorithms.[177] As 
patient-reported outcomes, respiratory symptoms are gaining interest in 
clinical research.[178] Our observation that routine monitoring data predicted 
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ICS/LABA treatment supports the utility of telemonitoring as a method to 
study pulmonary outcomes. 
 
Patients who initiated ICS/LABA treatment but did not prolong it after 2 years 
were different than those who continued for more than 2 years, but these 
patients are interesting subgroup of individuals to further explore as well. 
Whereas reasons for their discontinuation are unclear, our results suggest this 
subgroup might also have increased risk for poor health outcomes based on 
their increased intensity of WTC exposure, wheeze, dyspnea, and lower lung 
volumes. It is also possible that this group consisted of both individuals who 
recovered well from their lung disease and therefore no longer needed 
treatment and individuals who would benefit of prolonged ICS/LABA 
treatment but failed to adhere to their chronic treatment. This latter group of 
individuals might especially benefit from increased monitoring of their 
symptoms and lung function over time to prevent further deterioration. 
 
A potential weakness of our study is limited generalizability, because the 
FDNY cohort experienced a massive dust exposure and only included 
previously healthy males. We also acknowledge there may be unmeasured 
confounds, which is possible in all observational research. A strength of this 
investigation is comprehensive longitudinal data with little loss to follow-up, 
reducing the potential for selection bias. Drug use was objectively measured 
and the proportion of individuals who were persistent in ICS/LABA use 
> 2 years was 69%. This is slightly better than a study of real-world use of 
ICS/LABA in UK asthma patients, which found a proportion of patient 
persistence between 53% and 69% after only 1 year.[179] This slightly better 
adherence could be due to the increased monitoring and reimbursement of 
treatment within the WTC program. 
 
Further research in occupational cohorts is needed to assess if routine 
respiratory symptom monitoring and hand-held spirometry can identify at-risk 
individuals who would benefit from subspecialty testing for obstructive 
airway disease. 
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In summary, we identified patient characteristics associated with ICS/LABA 
treatment. We observed that increased respiratory symptoms and lower FEV1 
are persistent factors associated with treatment. Occupational cohorts that 
experience irritant exposures may require screening for obstructive airway 
disease with the goal to treat lung injury before development of abnormal lung 
function. 
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IV. DRUG-RELATED FACTORS 
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IV.1.  Effect of inhaled corticosteroids on FEV1 trajectory in 




In healthy individuals, normal aging affects pulmonary function, resulting in 
reduction in lung function but seldom leading to symptoms. The expiratory 
volume exhaled during the first second of a forced breath (FEV1) declines 
around 30 mL/year in men and 25mL/year in women from middle age 
adulthood onwards.[30] A greater than age-related decline in FEV1 is called 
an accelerated decline. Depending on the degree of decline, respiratory 
symptoms and general impact might be present.[180] Despite normal lung 
function at early adulthood, an accelerated decline in lung function is one of 
the pathways found to lead to chronic obstructive pulmonary disease 
(COPD).[31]  
Exposure to dust and products of combustion at the collapse of the World 
Trade Center (WTC) resulted in an acute drop of lung function and high 
incidence of reactive airways disease (asthma) in rescue and recovery 
workers.[29,43,44] Immediately after 9/11/2001, the Fire Department of the 
City of New York (FDNY) instituted a longitudinal medical monitoring 
program that performed screening pulmonary function tests and collected 
health information via computer-based questionnaires.[52] Furthermore, 
FDNY resourced a treatment program staffed with pulmonologists to provide 
subspecialty pulmonary evaluation and treatment at no cost to the participants. 
Longitudinal data from these monitoring and treatment programs has 
identified a subgroup of WTC-exposed firefighters with an accelerated decline 
in FEV1.[46] Importantly, accelerated FEV1 decline in itself is not an 
indication for treatment according to guidelines for asthma or COPD.[8,11] 
The effect of pharmacotherapy on FEV1 decline has been questioned for over 
decades.[92] Post-hoc analyses of randomized controlled trial data showed the 
largest effect for ICS/LABA compared to placebo on the rate of FEV1 decline 
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in COPD patients.[93,94] In asthma, there is no conclusive evidence that ICS 
prevents long-term accelerated decline in lung function and mortality, 
occurring in a subgroup of asthma patients.[91] Furthermore, there is a lack 
of real-life evidence from observational studies analyzing the effect of inhaled 
steroids (ICS) on lung function over time. Since a proportion of WTC-exposed 
firefighters are suffering from continued accelerated FEV1 decline, we aimed 
to analyze the effect of ICS-containing treatment on FEV1 trajectory in this 
WTC-exposed cohort.  
IV.1.2. Methods 
IV.1.2.1. Source population and data sources 
The source population included 10,166 World Trade Center (WTC)-exposed 
male firefighters who were actively employed by FDNY on 11 September 
2001 (9/11), consented to research and had at least one post-9/11 monitoring 
exam between 11 September 2001 and 10 September 2017. Since individuals 
were active firefighters on 9/11, who are banned from the job when they 
develop asthma, we assumed they were not on an ICS-containing inhaler on 
9/11. 
Data on demographics, height, weight, smoking status, WTC exposure level 
(defined by initial arrival time at the WTC site), spirometry measurements, 
respiratory symptoms and blood eosinophil counts were retrieved from the 
FDNY employee database and/or were assessed during the first routine 
medical monitoring exam post 9/11.  
IV.1.2.2. Study population and exclusions 
Figure 24 shows the flow chart of the study population, excluding individuals 
limited by longitudinal data and therefore not eligible for the calculation of 
time-varying propensity scores. 
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Figure 24 – Flow chart of the study population. The source population included 
10 166 World Trade Center (WTC)-exposed male firefighters who were actively 
employed by Fire Department of the City of New York (FDNY) on 11 September 
2001, consented to research, and had at least one routine medical monitoring exam 
between 11 September 2001 and 10 September 2017. After applying exclusion 




Male WTC-exposed FDNY 
firefighters with ≥1 post-9/11 
medical monitoring exam
11 Sept 2001 – 10 Sept 2017
n = 10 166
Population with 
monitoring data
n = 10 106
Individuals missing symptoms, weight or lab (n=60) 
Population with 
longitudinal data
n = 9 771
Individuals having ICS initiation before first monitoring 
exam (n=335) 
Study population
n = 7 604
Individuals having <5 interval containing an exam  (n=1171) 
Individual missing ≥2 consecutive intervals  (n=996) 
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IV.1.2.3. ICS treatment exposure 
The exposure of ICS-containing treatment, versus no ICS-containing 
treatment was studied. ICS-treatment was defined as ICS monotherapy or 
combination with LABA or LAMA/LABA, the majority in multiple devices. 
Medication data were obtained from the FDNY electronic medical record 
(EMR) and the pharmacy claims database. The initiation date was defined as 
the date of the first recorded prescription claim or EMR note, whichever 
occurred first. Once initiated, individuals were considered as staying on the 
ICS-treated trajectory until the end of study (n=2,593) but their actual days 
covered by ICS was calculated by proportion days covered (PDC) per 2-year 
interval.[181] Their adherence was approximated by the sum of days supplies 
of the pharmacy claims, divided by the total of days per 2-year interval. The 
highest PDC over all treated intervals in an individual defined the ICS 
adherence type of that individual: <50% as very low adherent (n=1050), 
50- 80% as low adherent (n=333), 80-120% as ICS adherent (n=721), >120% 
as overuser (n=285). Before the time claims data was available (December 
2006), adherence was calculated based on the EMR notes. The PDC was 
estimated for each distinct 270-day course in which ICS treatment was 
reported in the EMR notes. This duration was based on the extrapolation of 
EMR notes to claims data after December 2006. 
A sensitivity analysis of the main analysis used pharmacy claims data as the 
primary medication data source. Before claims data was available (December 
2006), medication use was estimated based on the EMR notes.  
IV.1.2.4. Outcome 
The main outcome of interest was FEV1 trajectory over time (mL/year). 
IV.1.2.5. Statistical analyses 
Descriptive statistics are reported as proportions (%) for categorical variables 
and means (with SD) for continuous variables. Differences between groups 
were evaluated by chi-squared and t tests, respectively. 
Propensity scores  
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Propensity scores for ICS initiation were calculated per 2-year interval post 
9/11 using logistic regression models. When multiple exams occurred in the 
same 2-year time interval the first exam with complete data was used. Time-
independent variables as age, race, height, baseline FEV1 and WTC exposure 
level were included. In addition, time-dependent covariates as smoking and 
retirement status, weight, respiratory symptoms, blood eosinophil count and 
co-medications potentially impacting on FEV1 trajectory (oral corticosteroids, 
short-acting or long-acting bronchodilators, leukotriene receptor antagonists, 
theophylline or biologicals) were included in the models. Respiratory 
symptoms of cough, wheeze, dyspnea and provocability were combined as a 
5-level variable, comparing those that had one, two, three or four respiratory 
symptoms versus none of those four. Provocability was evaluated by asking 
about symptoms of cough, wheeze, dyspnea, or chest tightness when exposed 
to smoke, fumes, odors, dust, allergens, temperature or humidity extremes, or 
physical activity. When individuals reported at least one respiratory symptom 
of provocability on the medical monitoring questionnaire, they were 
considered as having provocability. Missing covariates were imputed by data 
from the most recent observed prior interval.[182]  
 
Inverse probability of treatment weighting (IPTW) analysis 
Inverse probability of treatment weighting (IPTW) was used to control for 
possible time-varying confounding of covariates associated with both 
outcome and initiation of ICS-containing treatment.[183] First, inverse 
probability of treatment weights were assigned, based on the inverse of their 
probability of initiating treatment, as estimated by the propensity score.[183] 
Weights in the first 2-year interval, considered as baseline, were one for all 
individuals, but could change over time dependent on the probability of ICS 
initiation. In ICS-treated individuals, once ICS was initiated, weights were set 
to one in the subsequent intervals. 
Second, FEV1 trajectories were estimated for ICS-users versus no ICS users, 
using linear mixed effects models with random intercepts. The first model 
estimated mean absolute FEV1 values for the ICS-treated versus the non-
treated group for each 2-year interval between 11 September 2001 and 10 
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September 2017, weighted for the propensity score weights per interval. A 
separate model estimated an average FEV1 slope throughout follow-up, also 
weighted for the propensity score weights per interval. 
 
Propensity score matched analysis  
Propensity score matched analyses were additionally performed to confirm 
that the ICS effect was not driven by differences in baseline lung function. 
Matches were created within a subgroup of individuals with similar baseline 
lung function and early initiation of ICS, defined by start of an ICS-containing 
treatment between 11 September 2001 and 10 September 2005, and controls 
in the same time period (n=1814). The earliest lung function exam was used 
for the propensity score matching. The optimal matching method was used 
with 1:1 matching and a caliper around 0.2 times the SD of logit of the 
propensity score.[184] The baseline characteristics were assessed for balance 
through the appropriate testing procedure for the matched dataset. Linear 
mixed effects models estimated mean absolute FEV1 for ICS-treated versus 
non-treated. A separate model estimated a mean FEV1 yearly slope throughout 
follow-up. 
 Characteristics of response to ICS-containing treatment were assessed 
within this subset of users with early initiation post-9/11 of ICS treatment. 
Therefore, ICS-treated individuals of the matched analyses were grouped into 
responders and non-responders. Responders were defined as having an 
individual FEV1 slope after treatment initiation calculated by mixed effects 
models greater than or equal to the group median slope for ICS-initiated 
individuals (-33.0 mL/y), which means an FEV1 decline less than the median. 
Baseline characteristics and early biomarkers were compared. The biomarker 
analysis included blood eosinophil counts before the ICS initiation date, after 
excluding individuals who already received oral steroids (n=42). A subgroup 
had also immunoglobulin concentrations (including IgA) assayed with 
HGAMMAG-301K (EMD Millipore) on serum drawn between October 2001 
and March 2002 and (n=147). Last, systemic antibiotic and oral corticosteroid 
use before the date of ICS initiation was assessed, as proxies for respiratory 
exacerbations.  




Data analyses were performed using SAS 9.4 (SAS Institute Inc. Cary, NC). 
Figures were made using SAS and Microsoft Excel. 
 
IV.1.3. Results 
IV.1.3.1. Descriptive Statistics 
Table 19 shows the baseline characteristics of the study population which are 
comparable of those of the source population. Among the study population, 
the ICS treated group has a non-significant larger proportion of ever smokers 
(p=0.23), significant larger proportion of individuals with high WTC exposure 
level (p<0.001) and significant lower baseline FEV1 values (p<0.001) 
compared with the non-ICS treated group. 
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Table 19. Demographics of the study population, comparing the ICS non-
treated with the ICS-treated population 














Age on 9/11 40.4 ± 7.4 39.5 ± 7.2 39.1 ± 7.5 40.1 ± 6.7 
Height 177.2 ± 6.4 177.0 ± 6.4 176.9 ± 6.3 177.2 ± 6.5 
Smoker, ever* 2669 (26.3) 1849 (24.3) 1197 (23.9) 652 (25.1) 
Race    
White  9557 (94.0) 7190 (94.6) 4723 (94.3) 2467 (95.1) 
Black  254 (2.5) 148 (2.0) 114 (2.3) 34 (1.3) 
Other  355 (3.5) 266 (3.5) 174 (3.5) 92 (3.6) 
WTC exposure level     
Morning of 9/11 1671 (16.4) 1199 (15.8) 691 (13.8) 508 (19.6) 
Afternoon of 9/11  
or 12/9/2001  
7237 (71.2) 5509 (72.5) 3651 (72.9) 1858 (71.7) 
13/9-24/9/2001 1258 (12.4) 896 (11.8) 669 (13.4) 227 (8.8) 
Baseline FEV1 (L)* 3.99 ± 0.68 4.05 ± 0.66 4.11 ± 0.65 3.92 ± 0.66 
Baseline FEV1 % pred* 96.7 ± 13.8 97.4 ± 13.4 99.0 ± 12.9 94.3 ± 13.9 
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IV.1.3.2. IPTW analysis of ICS treatment versus no ICS 
The average slope throughout 16 years of follow-up after 9/11 was -33.8 
mL/year (95% CI -34.5; -33.1) when non-ICS treated versus -31.4 mL/year 
(95% CI -32.8; -30.0) when ICS-treated. ICS demonstrated a significant 
improvement in FEV1 decline with an average slope of 2.4 mL/year (95% CI 
0.9; 3.9 p=0.002). Figure 25 shows the trajectories by 2-year intervals 
throughout follow-up. 
 
Figure 25 – FEV1 trajectory by ICS-treatment weighted for inverse probability of 
treatment weights. The mean (±95% CI) trajectory of absolute FEV1 is shown in each 
2-year interval between 11 September 2001 and 10 September 2017. The blue graph 
corresponds to the ICS non-treated subgroup (n = 6808) and the red to the ICS-
treated subgroup (n=2584). In the first two 2-year intervals, the decline is rather 
steeper in the non-treated ICS group compared with the ICS-treated. Thereafter both 
trajectories remain about parallel over time. 
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The results of the sensitivity analysis using pharmacy claims data as the 
primary medication data source, were similar to the primary analyses. The 
average slope throughout 16 years of follow-up after 9/11 was -33.7 mL/year 
(95% CI -34.4; -33.0) when non-ICS treated versus -31.6 mL/year (95% CI -
33.0; -30.1) when ICS-treated. The effect of ICS, primary based on claims 
data, showed a significant improvement in FEV1 decline with an average slope 
of 2.1 mL/year (95% CI 0.6; 3.7 p=0.006). 
 
After adjusting for adherence to ICS, measured as proportion days covered 
(PDC) per interval, the average effect of ICS was estimated on 4.6 mL/year 
throughout 16 years of follow-up post-9/11. When stratifying treated 
individuals by ICS adherence type, defined by the highest PDC per interval, 
those who were very low adherent (PDC <50%) had a worsening in FEV1 
decline of 12.1 mL/year, low adherent (PDC 50-79%) had an improvement in 
FEV1 decline of 4.0 mL/year, adherent (PDC 80-120%) had an improvement 
in FEV1 decline of 13.0 mL/year and overusers (PDC >120%) an 
improvement in FEV1 decline of 9.6 mL/year (Figure 26).  
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Figure 26. Change in FEV1 slope stratified by adherence type, defined by highest 
proportion days covered per interval.  
 
IV.1.3.3. Propensity score matched analyses 
 
Using propensity score matching, we examined whether the ICS effect was 
driven by differences in baseline lung function. A subgroup of individuals 
with similar baseline lung function and with ICS initiation between 11 
September 2001 and 10 September 2005 (n=907) was matched with control 
individuals in that time period (n= 907). The average FEV1 slope throughout 
follow-up was -31.9 mL/year (95% CI -33.7; -30.1) for non-ICS treated versus 
-33.9 mL/year (95% CI -35.6; -32.3) for ICS-treated, including spirometry 
measurements from ICS initiation throughout follow-up. There was a non-
significant worsening in FEV1 slope of 2.0 mL/y (95% CI -4.5; 0.4 p=0.10) in 























Adherence type (proportion days covered)
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in non-adherent users (PDC<80%; n=1375) and +10.7 mL (95% CI 1.5; 19.8 
p=0.02)  in adherent users (PDC ≥80%; n=439). 
 
Among this earliest matched group, responders on ICS treatment were defined 
as having an individual mixed effect modeled FEV1 slope greater than the 
mean group slope for ICS-initiated individuals (n=475). Their early 
characteristics were compared with non-responders defined as ICS-treated 
individuals with a slope less than the average of those treated (n=432). ICS 
responders were younger, had a significantly smaller proportion of ever 
smokers, lower baseline FEV1 % predicted, a significantly lower proportion 
of adherent individuals and shorter average treatment duration (Table 20).  
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Table 20. Characteristics of responders versus less-responders to ICS-
containing treatment for ICS treatment initiation in intervals 1-2 
¶ Responders: FEV1 post initiation slope >=-33.0 mL/y and non-responders <-33.0 mL/y; 
¥p<0.05 between 2 groups *first post-9/11 exam; $ n=213 missing eosinophil count before ICS 
initiation date, n=42 excluded because of oral steroid treatment; #serum IgA ≤ 70 mg/dL in 







Age on 9/11 39.4 ± 6.2 42.1 ± 6.9¥ 
Height 177.4 ± 6.6 177.5 ± 6.8 
Smoker, ever* 87 (18.3) 122 (28.2)¥ 
Race   
White  452 (95.2) 409 (94.7) 
Black  5 (1.1) 4 (0.9) 
Other  18 (3.8) 19 (4.4) 
WTC exposure level 
Morning of 9/11 113 (23.8) 100 (23.2) 
Afternoon of 9/11 or 12/9/2001 327 (68.8) 297 (68.8) 
13/9-24/9/2001 35 (7.4) 35 (8.1) 
FEV1 absolute (L)* 3.87 ± 0.64 3.89 ± 0.68 
FEV1 % predicted* 92.3 ± 13.6 94.3 ± 14.1¥ 
Cough* 339 (71.4) 297 (68.8) 
Wheeze* 175 (36.8) 174 (40.3) 
Shortness of breath* 232 (48.8) 230 (53.2) 
Blood eosinophils (cells/µL) *$ 193.7 ± 124.1 210.4± 126.4 
Low serum IgA, n (%)*# 12 (14.8) 9 (13.6) 
Antibiotic use pre ICS initiation, n (%) 106 (22.3) 106 (24.5) 
Oral steroid use pre ICS initiation, n (%) 23 (4.8) 20 (4.6) 
ICS adherence type‡, PDC≥80%, n (%) 140 (29.5) 172 (39.8)¥ 
ICS duration (years) 3.4 ± 5.1 4.2 ± 5.6¥ 
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IV.1.4. Discussion 
In this previously healthy, WTC-exposed firefighter cohort, the effect of ICS-
containing treatment on FEV1 trajectory was studied. A longitudinal analysis 
using IPTW, showed that ICS-containing treatment altered lung function 
trajectory. We observed an average improvement in FEV1 decline of 
2.4 mL/year compared with no ICS treatment, and even 4.6 mL/year when 
adjusting for adherence to ICS.  
 
The 9/11 disaster causing an intense dust cloud led to a transient inflammatory 
reaction to the inhaled dust, associated with an acute drop in lung 
function.[29,43,44] This inflammation could be targeted with ICS, since ICS 
reduce airway inflammation and hyperresponsiveness by altering the 
production of mediators associated with inflammatory cells in the 
airways.[66,67] However, there might be different underlying disease 
endotypes with variances in ICS responsiveness, as suggested by earlier 
observations among WTC-exposed firefighters responding better to 
ICS/LABA treatment when initiated sooner after 9/11.[185] Additionally, the 
ICS responder characterization showed that responders had a smaller 
proportion of ever smokers. Smoking is a known modifier of ICS response, 
leading to a reduced effect in asthma and COPD cohorts.[186,187] 
Interestingly, blood eosinophils count appeared not-significantly different in 
responders versus ICS-non responders. We therefore could not replicate in our 
firefighter cohort the beneficial response to ICS associated with high blood 
eosinophils observed in patients with asthma and COPD.[188–190]. The 
lacking availability of a blood eosinophil count close before ICS initiation 
might have played a role here. Alternately, WTC-related irritant-associated 
lung injury disease might have another underlying disease endotype, with 
different factors predicting ICS response. Pharmacogenomics studies showed 
genetic variants might also lead to a different response to ICS.[191–193] 
 
We observed an average improvement in FEV1 decline of 2.4 mL/year among 
ICS treated compared with non-treated individuals, with an effect of 
4.6 mL/year when taking adherence into account. This effect is in line with 
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the effect observed in populations with chronic, ongoing exposure and 
inflammation due to noxious particles, such as smoking. In a recent systematic 
review, only including larger trials with at least 1 year follow-up, concluded 
to a 5.0 mL/year reduction in FEV1 decline for active COPD treatments and 
7.3 mL/year in a subgroup analysis of ICS-containing therapies.[194] The two 
largest randomized controlled trials (RCTs) were TORCH (TOwards a 
Revolution in COPD Health) and SUMMIT (Study to Understand Mortality 
and Morbidity in COPD), which showed a reduction of ICS/LABA on FEV1 
decline of 16 mL/year and 8 mL/year compared with placebo and an effect of 
ICS monotherapy of 13 mL/year and 8 mL/year compared with placebo, 
respectively.[93,94] Lung function was studied as a secondary endpoint, 
therefore post-hoc analyses were used to study the effect of ICS, LABA, 
ICS/LABA vs placebo on the rate of FEV1 decline. Looking in detail at these 
short-term trajectories, first a big volume effect at 3-6 months is observed, 
with thereafter a decline in FEV1 slope which is more parallel with control 
groups. This volume effect can partially be explained by relieving the chronic 
bronchoconstriction in those COPD patients.[195] The applicability of these 
results towards subjects heavily exposed to noxious particles or gases but not 
(yet) diagnosed with COPD, was unknown. The observed effect of ICS when 
stratified by adherence type, can be seen as a dose-response effect. However, 
overuse of ICS might have the risk of systemic side effects without a more 
pronounced effect. Our overall observed ICS effects are lower than those 
found in the TORCH and SUMMIT trials. When stratifying by adherence 
type, the effect is in the same range seen as the trials’ effect. This can be 
explained by the fact that the adherence achieved in clinical trials was not 
reached in real life. 
 
A strength of this investigation is the comprehensive longitudinal data with 
little loss to follow-up reducing the potential for selection bias. Another 
strength is the objective measure of the treatment exposure. A weakness of 
our cohort is the specific setting of a massively dust-exposed cohort including 
only previously healthy males, which limits the generalizability. Inverse 
probability of treatment weighting, a type of propensity score method, was 
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used to analyze treatment effects from these observational data. Propensity 
scores are used to reduce selection bias by equating groups based on observed, 
time-varying confounders related to treatment assignment.[183] Selection 
bias is a discrepancy between the estimated treatment effect and the true 
treatment effect due to systematic pre-intervention differences between 
members of treated and untreated groups.[196] In observational studies, when 
participants are not randomly assigned to groups, observed pre-intervention 
differences cannot be assumed to be random and selection bias is highly likely 
when analyzing treatment effects. Unfortunately, the inverse probability of 
treatment weighting method also has its limitations. Propensity scores are 
valuable in controlling for measured confounding, but cannot control for 
unmeasured confounding either.[197] Using a mixed effects model as the 
outcome model, a possible effect might also be averaged out in the overall, 
average FEV1 trajectory. Concerned about differences in baseline lung 
function, we performed a matched analysis for early ICS initiation to evade 
regression to the mean. This analysis was performed in a subgroup, because 
for the most extreme values of FEV1, we were not able to find a match for 
every ICS-treated individual. Therefore, the resulting ICS effect is not 
representative of the entire group of ICS-treated individuals, since the 
individuals with worse baseline lung function were less presented in this 
analysis. The observed effect was therefore probably underestimated. 
Furthermore, due to the lack of statistical power in this subgroup analysis, we 
cannot state these associations of potential biomarkers and ICS response on 
FEV1 decline are final. More research is needed to further explore the 
associations of these potential biomarkers and ICS response. Ideally, there 
should always be a systematic baseline blood drawn should prior to ICS 
initiation. 
 
In conclusion, the effect of ICS treatment resulted in a 2.4 mL average 
reduction in FEV1 decline over 16 years of follow-up. When taking adherence 
to ICS into account, the effect improved to 4.6 mL/year. More observational 
research in general cohorts is needed to further assess the effect of ICS on 
FEV1 decline.  
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IV.2. Impact of community pharmacist counseling on adherence 
to inhaled corticosteroids and asthma control 
 
IV.2.1. Introduction 
Asthma is a prevalent chronic airway disease, often starting during childhood 
and affecting individuals of all ages.[198] Its worldwide prevalence was 
around 300 million individuals in 2016 according to the World Health 
Organization, with an estimated rise to 400 million expected by 2025.[199] In 
Belgium, the prevalence is around 7%.[200] Despite the wide range of 
adequate asthma medication available, only 50% of patients benefit 
sufficiently from it. Inhaled corticosteroids (ICS) are the cornerstone of 
asthma therapy.[65,201] However, adherence to controller medications and 
inhaler technique, remains low.[96] Uncontrolled asthma can lead to 
exacerbations, disability, and even death, with a large socio-economic burden 
associated. Therefore, asthma requires global attention and appropriate patient 
education, to improve patient’s outcomes.[202]  
Pharmaceutical counseling (PC) interventions have proven to improve 
adherence to controller medication and asthma control, reducing emergency 
department visits and hospital admissions and so decreasing total health 
costs.[108,109,203,204] In addition, one recent meta-analysis confirmed that 
PC interventions can effectively contribute to improved medication adherence 
in asthma patients[110], but another meta-analysis could only confirm an 
improved inhaler technique and not adherence in asthma patients.[205] 
However, data on real-life impact of these PC interventions are lacking, 
particularly in difficult-to-control and severe asthma patients, which are 
associated with a substantial health and economic burden.[206,207] 
The overall aim of this study was to evaluate whether PC interventions 
improve adherence to chronic inhaler therapy among difficult-to-control 
asthma patients using real-world, nationwide data. We hypothesized that PC 
interventions improve ICS adherence and improved adherence results in a 
better asthma control. 
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IV.2.2. Methods 
The source was the BelPhar database, which monthly collects reimbursement 
claims and patients’ demographics from all community pharmacies affiliated 
with the Association of Pharmacists Belgium (APB; the Belgian federation of 
independent community pharmacies). At national level, the registered data 
represents around 85% of all Belgian community pharmacies and corresponds 
to approximately 78% of all national reimbursed community pharmaceutical 
dispenses.  
The source population contained all patients aged 5+ in the BelPharData with 
at least one ICS dispensing in the period 1/1/2017-31/12/2017, with the date 
of first dispensing in 2017 defining the reference date. The asthma-related 
drug use (detailed in Table 21) of this population was extracted from exactly 
one year before to exactly one year after the reference date. The method used 
for the data extraction is illustrated in  Figure 27. Chronic ICS users were 
defined as patients in the source population who had at least one ICS 
dispensing in the 12 months before and in the 12 months after the reference 
date. The study population, most representative of an asthmatic population, 
included chronic ICS users aged 5-40 years. Index patients received at least 
one PC intervention within 90 days after ICS dispensing, as recorded by the 
database. The protocol-based PC intervention consisted of two counseling 
interviews offered by the community pharmacist and targeted both incident 
asthma patients starting ICS treatment and prevalent asthma patients with 
difficult-to-control disease despite chronic ICS treatment. Our study 
population derived from this latter group with difficult-to-control asthma 
prescribed long-term ICS therapy, who received a PC intervention. Asthma 
control was assessed by the occurrence of nocturnal awakening (‘how often 
did you wake up at night or early in the morning earlier than usual because of 
asthma symptoms?’) and reliever use (‘how often have you used your inhaler 
with fast-acting medication?’) in the past 4 weeks, according to GINA 
guidelines.[65] In case of any nocturnal awakening in the past 4 weeks and/or 
reliever use more than twice a week, the asthma was considered poorly 
controlled and an interview was scheduled at the community pharmacy. In a 
first interview the pharmacist assessed patients’ expectations, disease control 
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using Asthma Control Test, knowledge about asthma and medications, inhaler 
technique, adherence and the importance of adherence, side effects or 
corticophobia. Furthermore, the patient was educated about medication use 
(purpose, mechanisms of action, side effects, use of inhalers) and risks of non-
adherence and overuse of reliever medication, and possible questions were 
answered. A follow-up interview was offered three to six weeks later, to assess 
patient’s experience, detect remaining problems and check the evolution in 
patient’s medication use and knowledge. A sensitivity analysis stratified on 
the number of PC interventions compared ICS usage between patients who 
received 1 PC intervention (n=1119) with patients who received two or more 
interventions (n=231), both within 90 days after ICS dispensing.  
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Table 21. The most commonly used drugs for the treatment of asthma are subdivided 
by chemical subgroup, active substance and ATC code. 
Group Active substance ATC code 
Antibiotics Antibacterials for systemic use J01 
Biologicals Omalizumab R03DX05 
Biologicals Mepolizumab R03DX09 
Biologicals Benralizumab R03DX10 
ICS Salmeterol and fluticasone R03AK06 
ICS Formoterol and budesonide R03AK07 
ICS Formoterol and beclometasone R03AK08 
ICS Vilanterol and fluticasone furoate R03AK10 
ICS Formoterol and fluticasone R03AK11 
ICS Vilanterol, umeclidinium bromide and 
fluticasone furoate 
R03AL08 
ICS Formoterol, glycopyrronium bromide and 
beclometasone 
R03AL09 
ICS Beclomethasone R03BA01 
ICS Budesonide R03BA02 
ICS Fluticasone R03BA05 
LABA/LAMA Indacaterol, formoterol or olodaterol 
and/or aclinidinium, glycopyrronium, 
tiotropium or umeclidinium 
R03BB04-07, 
R03AL04-06 
OCS Methylprednisolone H02AB04 
SABA/SAMA Salbutamol R03AC02 
SABA/SAMA Fenoterol and ipratropium bromide R03AL01 
SABA/SAMA  Salbutamol and ipratropium bromide R03AL02 
ATC, anatomical therapeutic chemical; ICS, inhaled corticosteroids: LABA, long-
acting beta-agonists; LAMA, long-acting muscarinic antagonists; OCS, oral 
corticosteroids; SABA, short-acting beta-agonists; SAMA, short-acting muscarinic 
antagonists. 
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Figure 27 – An example of how the BelPharData was extracted for a fictional patient 
receiving the first ICS dispensing in 2017 on February 1st, 2017 (= reference date). 
The asthma-related drug history one year before ICS dispensing (February 1st, 2016) 
was observed in comparison to the drug use exactly 12 months after the reference 
date. 
 
The change in drug use from one year before to one year after the PC 
intervention was analyzed (Figure 27). Asthma-relevant drug use was the 
main outcome of interest, reported as drug usage for ICS and proportion of 
drug users for the other asthma medications. Drug usage for ICS was defined 
as the proportion of total Defined Daily Dose (DDD) of ICS and the number 
of patients receiving ICS. Proportion of drug users was defined as the number 
of patients receiving an asthma-related drug of interest divided by the total 
number of ICS patients. For SABA, antibiotics and OCS, the proportion drug 
users from one year before first ICS dispensing in 2017 (reference period) was 
compared with one year after. The ratio of controller-to-total (CTT) asthma 
medications, an overall proxy for adherence and asthma control, was derived 
from the reported drug use.[208,209] The CTT ratio was calculated by 
dividing the sum of prescription DDDs for controller medication (ICS, long-
acting beta-agonists [LABA]/long-acting muscarinic antagonists and 
biologicals) by total asthma medication (controller medication plus SABA). 
Since omalizumab was the only reimbursed asthma biological available on the 
Belgian market until the end of 2016 and more became available during 2017, 
we only analyzed the proportion of biological users post PC intervention. 
Controls for this analysis were defined as chronic ICS users aged 5-40 years 








February 1st, 2016 February 1st, 2017 February 1st, 2018
[2016] [2017] [2018]
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Confidence intervals for the group means were computed by the assumed 
mean method. Confidence intervals for the difference between two 
proportions were calculated using the Newcombe method.[210] P value <0.05 
was considered significant. Data analyses were performed using SAS 9.4 
(SAS Institute Inc. Cary, NC). Figures were made using Microsoft Excel 
16.45. 
IV.2.3. Results 
The BelPharData-based source population included 922 943 patients having 
an ICS dispensing recorded in 2017. Of this source population, 288 069 (31%) 
were chronic ICS users, of which 56 582 (20%) was aged 5 to 40 years. 
Among these 5-to-40-year-old asthma patients on chronic ICS therapy, about 
half (54%) were women and 6% received at least one PC intervention. 
Furthermore, 49% were SABA users, 51% were antibiotic users and 8% OCS 
users. The average ICS adherence was 36%, based on their DDD coverage in 
2017. The study population consisted of difficult-to-control asthma patients 
identified by the pharmacist in this group of chronic ICS users aged 5-40 
years, with at least one PC intervention within 90 days after the reference date 
(n=1350). Among those, 83% (n=1119) received one PC intervention and 
17% (n=231) received more than one intervention. 
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IV.2.3.1. Impact on asthma controller medication 
The primary analysis showed a significant increase of 43.3 DDD/patient in 
ICS usage with 125.9 DDD/patient (95% Confidence Interval [CI] 124.9-
126.9) in the year following the PC intervention compared with a usage of of 
82.6 DDD/patient (95% CI 82.0-83.2) the year before. (Figure 28). The CTT 
ratio went from 0.671 before to 0.749 after PC intervention, representing an 
increase of 0.078 (95% CI 0.075-0.081, p<0.05). 
 
Figure 28 – Bar chart showing results of the primary analysis of inhaled 
corticosteroids (ICS) usage one year pre-intervention (light gray filled) and one year 
post-intervention (dark gray filled) in 5-40 year-old difficult-to-control asthma 
patients with at least one PC intervention in 2017. This corresponds with an increased 
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A sensitivity analysis on the number of interventions showed a similar, 
significant increase in ICS usage in patients who received one PC intervention 
(n=1119; 83%) of 39.3 DDD/patient (Figure 29). Patients who received two 
or more interventions (n=231; 17%) showed a significant gain of even greater 
magnitude in ICS usage of 62.1 DDD/patient. 
 
 
Figure 29 – Bar chart graphs showing results of the sensitivity analysis of ICS usage 
among difficult-to-treat asthma patients when stratifying by the number of 
pharmaceutical counseling (PC) interventions. The subgroup of patients who received 
1 PC intervention (n=1119) had an evolution in ICS usage one year pre-intervention 
(light gray filled) from 79.8 to one year post-intervention (dark gray filled) of 119.1 
Defined Daily Dose (DDD) per patient. This resulted in an increased usage of 39.3 
DDD per patient. In addition, the subgroup of patients who received two or more 
interventions (n=231) showed an even a greater gain in ICS usage of 62.1 DDD per 
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IV.2.3.2. Impact on short-acting beta-agonist (SABA), antibiotic and 
oral corticosteroid (OCS) use 
 
Difficult-to-control 5-40-year-old asthma patients who received a PC 
intervention in 2017 experienced a reduction in reliever use. The proportion 
of SABA users decreased from 48.0% in the year before the intervention to 
46.2% in the year after the intervention, leading to a 1.8% (95% CI -2.0, 5.5%; 
p>0.05) lower proportion of SABA users (Figure 30). The proportion of 
antibiotic users was pronounced with 54.5% in the reference period. After the 
intervention a proportion of 52.7% was observed, leading to a 1.8% (95% CI 
-2.0,5.5%; p>0.05) lower proportion of antibiotic users compared with the 
reference period. Regarding the OCS use, there was a 1.1% (95% CI -
1.1,3.3%; p>0.05) higher proportion of OCS users, going from 9.0% in the 
year before to 10.1% the year after the intervention. 
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Figure 30 – Bar chart graphs representing the proportion of users of asthma-related 
drugs among difficult-to-control 5-40-year-old asthma patients who received at least 
one PC intervention in 2017. The proportion short-acting beta-agonist (SABA) users 
decreased from 48.0% pre-(light gray filled) to 46.2% post-(light gray filled) 
intervention, resulting in a 1.8% drop. The proportion antibiotic users decreased with 
1.8%, from 54.5% one year before the intervention (light gray filled) to 52.7% one 
year after the (light gray filled). Regarding the recorded oral corticosteroids (OCS) 
use, the proportion users increased with 1.1% from one year before the intervention 
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IV.2.3.3. Impact on biological use 
The proportion of biological users was 0.22% when analyzing biological use 
in the year after the reference date among difficult-to-control 5–40-year-old 
asthma patients who had a PC intervention. In chronic ICS patients aged 5-40 
years who never had an intervention (control group) on the other hand, the 
proportion of biological use was 0.30%. This indicates a 0.08% (95% CI -
0.36%,0.23%; p>0.05) lower absolute proportion of biological use in the study 
population receiving at least one PC intervention compared with a similar, 
chronic ICS user group never receiving this PC intervention. 
 
IV.2.4. Discussion 
We conducted a nationwide, observational study to investigate whether real-
world evidence can extrapolate the positive effect of PC interventions on 
adherence and asthma control in difficult-to-control asthma patients aged 5-
40 years. As a first part, the adherence to asthma controller medication, 
represented by ICS usage per year and CTT ratio, significantly increased in 
the year after the intervention. Furthermore, a nominal decrease in the number 
of SABA and antibiotic users was observed compared to their own reference 
period. Additionally, a lower proportion of biological users was seen in the 
intervention group compared with a control group in the post-intervention 
period.  
Our findings of an improved adherence to ICS and higher CTT ratio after PC 
intervention when using real-life data, is supporting earlier trial results on 
community pharmacy interventions.[108,204,211] However, in only one trial 
focused primarily on patients with difficult-to-control asthma, a community 
pharmacy intervention improved adherence.[203] The PC intervention in our 
study included an interview in which the community pharmacist assessed the 
patient’s disease control, knowledge and expectations, inhaler technique and 
adherence. A follow-up interview was offered routinely, but only happened in 
17%. Multiple interventions did lead to a higher increase in ICS usage, which 
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is in line with studies showing follow-up led to improved outcomes.[212,213] 
Adherence is of major importance because it will highly influence the 
expected pharmacological effect of that drug and the ability to treat the 
patient’s disease.[96,97] Since adherence often remains low, improving 
adherence is fundamental to the success of asthma management.[65] A 
systematic review concluded that better adherence to asthma controllers is 
associated with fewer severe asthma exacerbations.[214] Better asthma 
control scores were also reported by patients with better ICS adherence in a 
prospective cohort study.[104] Non-adherence leads to adverse outcomes, as 
higher healthcare utilization and costs, and reductions in health-related quality 
of life.[215] Besides better adherence, the observed increase in CTT ratio also 
reflects improved asthma control.[208] An earlier observation study found an 
0.1-unit increase in the ratio to result in a significant risk reduction of asthma 
exacerbations.[216] A higher CTT ratio is also associated with better asthma 
quality of life.[208] 
The findings that PC interventions improved medication adherence and 
asthma control highlights the role of the pharmacist in improving patients’ 
adherence in the healthcare system. Clinical pharmacist services delivered 
through telemedicine also positively impacted disease management and 
adherence.[217] With this increasingly central role that pharmacists play 
today, they could be seen as the guardian of adherence in chronic patients. 
This can be fulfilled in several ways, with or without using novel technologies. 
Regardless, the community pharmacist has the potential to further increase its 
impact on patients’ health through such interventions. 
 
Regarding reliever use, the amount of SABA users was found to be reduced 
in the pharmacist intervention group compared to their own reference period. 
These real-life observations are also in line with RCTs observing a decline in 
reliever medication use in the intervention arm.[108,203] This observed 
decline in reliever medication likely reflects the desirable improvement in 
asthma control. In literature, excessive use of SABA has been associated with 
insufficient controlled asthma, health-related costs and ultimately a higher 
mortality risk.[218,219] It has been shown that a significant number of these 
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health problems could be avoided. Appropriate use of maintenance medication 
is key in successful asthma management and optimal control reduces the need 
for reliever medication. In addition, the role of community pharmacies in 
supporting the asthma management plan was confirmed in a recent 
study.[220]  
As the severity of asthma increases, the patient may need OCS therapy more 
often to adequately manage the disease and associated 
exacerbations.[221,222] The percentage of OCS users in our study population 
of 9-10% was much lower than found in a recent review about difficult-to treat 
and severe asthma patients reporting OCS use ranging from 45-90% over one 
year.[201] This can be explained by some differences with these studies such 
as the age difference between our study population aged 5-40 years and 
several studies with a mean age above 50 years, use of self-reported OCS use 
and a focus on patients with severe asthma, which is a ‘truly severe’ subgroup 
of around 20% of the difficult-to-treat patients.[221] 
Moreover, the total percentage of biological users among the studied difficult-
to-treat asthma patients was low during the entire follow-up period. This can 
partially be explained by the fact that omalizumab was the only reimbursed 
biological available on the Belgian market until the end of 2016. This means 
that it was being implemented in common pulmonary practice in 2017. The 
low observed use of these add-on drugs is also in line with their proven 
efficacy within a very specific target group of very severe asthma, the high 
costs and under-studied long-term side effects in a young to adult population.33 
Another reason for the low number can be explained by the fact that some 
biologicals need to be administered in hospital setting and BelPharData is not 
capturing hospital pharmacy claims. It is important to avoid adding biologicals 
to the treatment regimen of all difficult-to-control asthma patients. If the 
inhaler technique and adherence are optimized according to GINA guidelines, 
the vast majority of asthma patients in the general population can be treated 
with conventional therapy.[65,223] Although an apparently small absolute 
decline of 0.08% was observed in the proportion of biological users in cases 
compared with controls, avoiding unnecessary and potential ineffective 
initiation of biologicals may reduce substantial drug costs.[224] This is the 
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main objective of asthma management in this target population. By improving 
adherence to controller medication, the group of difficult-to-control asthma 
patients is reduced to a small group of patients with truly severe asthma where 
biologicals can be considered. 
 
The main strength of this research is the large number of patients using ICS 
therapy registered in the database. This provided a recent and general picture 
of the current asthma burden on a national, Belgian level. We defined our 
study population as difficult-to-control asthma patients among chronic ICS 
users aged between 5-40 years. A higher prevalence of ICS usage in our 
population among patients aged 40 years and over suggested a higher 
proportion of COPD treated with ICS-containing therapy or asthma/COPD 
overlap, and therefore was considered not most representative for an asthma 
population.[65] Chronic ICS users per definition, would already be on ICS 
treatment the year before the intervention and continue at least until the year 
after. Therefore, they are representative for patients with asthma, which is a 
chronic disease. In addition, the database contains extensive information that 
offered the opportunity to observe various factors related to disease control. 
This included objective medication data, such as the use of reliever 
medication, medications treating exacerbations and add-on drugs. 
Additionally, using the BelPharData had the great advantage of observing a 
large amount of PC interventions and patient data in the general population. 
This database also created the opportunities to perform longitudinal analyses 
of unidentified asthma patients and their corresponding drug profile.  
An important limitation of this study is the difficulty to clearly identify asthma 
patients, especially for a control group. The well-considered study design 
made it possible to not only to do an intra-patient comparison, taking their 
own period of time before the PC intervention as reference, but also to 
compare between patients receiving and not receiving the pharmacist 
intervention, to account for possible time-trend bias. The control patients used 
for the analysis of biologicals never received an intervention, meaning that 
there was no pharmacist assessment as to whether these ICS users were 
actually patients with asthma. These probably different patient groups make 
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comparative research challenging. Another limitation is ICS usage as a 
measure of adherence. We assumed that an increase in ICS usage reflected 
improved adherence through the PC intervention, but theoretically it could 
also be due to the need for a higher ICS dose in uncontrolled disease. 
Moreover, the observed differences in proportion of users of asthma-related 
drugs were rather small. This may be caused by a lower number of patients in 
the study population by limiting the definition to only difficult-to-control 
asthma patients among chronic ICS users aged 5-40 year. In addition, there 
was no control over the quality of the way the intervention was carried out, 
since this was a real-life observation. Although, participating pharmacists 
were offered training, there is undoubtedly a difference in the way pharmacists 
conduct the counseling interviews and how much time and effort they had 
invest in it. Nevertheless, the study results suggest that the intervention 
generally contributes to an average improvement in the asthma patients’ 
health. Finally, there are some limitations on using CTT ratio as a measure for 
adherence and asthma control. First, a short beta-agonist might be used before 
exercising, which reflects a good health and disease control. This will 
overestimate the use of reliever medication taken for poor asthma control and 
so underestimate the CTT and asthma control. Second, there will be asthma 
patients on low dose ICS combined with the LABA formoterol as 
‘maintenance and rescue therapy’. This would mean that the ICS and LABA 
do not always reflect a good asthma control, since they could also be used as 
relievers, but would sometimes have been misclassified as controllers when 
calculating a CTT ratio. Since 2019, GINA guidelines recommends all 
individuals with asthma receiving ICS-containing controller treatment with 
for mild asthma as-needed low dose ICS combined with the LABA 
formoterol.[65,68] However, this was not yet the case in 2017, when our data 
was collected. 
In summary, the results of this real-world observational study indicate that PC 
intervention improves adherence to ICS controller therapy and asthma control 
in difficult-to-treat asthma patients. This study suggests that community 
pharmacist counseling benefits the management of patients’ asthma on a 
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national level and supports a follow-up interview, especially in all difficult-
to-control asthma patients. 
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V. DISCUSSION AND CONCLUSION 
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To improve response to inhaled corticosteroids (ICS), host factors, drug-
related and environmental factors influencing treatment response, were 
analyzed. Host factors included characterization of disease type and 
identification of individuals at risk for the development of World Trade Center 
(WTC)-related lung injury. Early blood biomarkers, such as high eosinophils 
and low IgA, were found to be risk factors for irritant-associated lung injury 
years later. Additionally, lower spirometric values and respiratory symptoms 
were associated with ICS/LABA treatment. As drug-related factors studied, 
an improved adherence among ICS-treated individuals resulted in better 
asthma control. Furthermore, ICS treatment among WTC-exposed individuals 
led to an average 2.4 mL/year improvement in FEV1 decline compared with 
non-treated. Finally, regarding environmental factors, we observed that an 
increased level of WTC exposure was associated with ICS/LABA treatment 
shortly after 9/11 and active firefighting later in the follow-up. In addition, 
smoking was a predictor of a poorer response to ICS treatment on FEV1 
decline. 
 
V.1. Effect of ICS treatment on FEV1 decline 
An average improvement in FEV1 slope of 2.4 mL per year resulting from 
ICS-containing treatment, might seem small. However, when putting it in 
relevance of the average age-related decline, a proportion of 2.4 mL over an 
age-related decline of 25 mL to 30 mL is about an 8-10% slowing of 
longitudinal FEV1 loss, which might be clinical meaningful. Furthermore, it 
is the overall average result of the entire study population. This means on an 
individual level, there will be people with worsening accelerated decline and 
there will be people with a far more pronounced beneficial effect, where ICS 
was able to close the gap again after initial lung function loss. This was clear 
when analyzing the average change in FEV1 post-initiation compared with 
pre-initiation stratified by initiation time related to the 9/11 disaster. Initiation 
of ICS between 11 September 2001- 10 September 2005 led to a pronounced 
improvement in FEV1 decline, whereas initiation between 11 September 
2009- 10 September 2017 was not effective. This remarkable finding is of 
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clinical relevance in today’s practice, almost 20 years after the 9/11 disaster. 
If ICS-containing treatment does not slow FEV1 decline in a subset of patients 
developing COPD due to accelerated FEV1 decline, research into alternative 
treatments seems appropriate. 
 
V.2. Host-intrinsic predisposition 
We assessed whether biomarkers as high blood eosinophils and low IgA could 
predict a beneficial response on ICS treatment. Low IgA tended to be 
predictive, but blood eosinophils were not predictive. The heterogeneity of 
clinical presentation and disease course makes the evaluation of treatment 
response difficult. Identifying biomarkers to better predict treatment response 
is a crucial step to improve the selection of a treatment matching the individual 
patient’s needs. We observed high eosinophils and low IgA were associated 
with elevated risk on lung injury years later. Also, elevated IgE and IL-4 were 
associated with post-9/11 lung injury. The finding that high eosinophils were 
already higher pre-9/11 suggest the presence of patient-intrinsic susceptibility 
to developing obstructive airway disease. Similarly, low IgA drawn soon after 
9/11 was identified as a risk factor for the development of lung injury years 
later. Our longitudinal observation reveals that the FEV1 of this low IgA 
subgroup was already lower pre-9/11 and remained lower throughout follow-
up after 9/11. This can also suggest a patient-intrinsic susceptibility for 
patients with low IgA as a result of an intense, but transient inflammatory 
response to inhaled particulates.  
Eosinophils are the best studied biomarker in obstructive airway 
diseases, with testing of eosinophils count in blood being widely available. 
Elevated blood eosinophil count is a biomarker of increased exacerbation rate 
after ICS withdrawal in COPD patients.[154,225] Although blood eosinophil 
count appears to be a promising biomarker for corticosteroid response in 
COPD, the selection of patients with a beneficial response to specific 
interventions is generally still unsatisfactory.[83,189,226] There might also be 
underlying genetic factors associated with the inflammatory response to WTC 
exposure, explaining the difference in response to ICS for the treatment of 
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post-9/11 lung injury. Genetic variations also influence the response to ICS 
treatment, which has been examined by genome wide association studies 
(GWAS) examining ICS response.[191,227] In COPD, the identification of 
the pharmacogenomic factors determining the response of patients to ICS may 
guide its use of clinical practice.[192] 
 
V.3. Environmental factors 
The environmental factors are modifiable components that can alter the 
intensity of the treatment effect. We identified smokers having a poorer ICS 
response on FEV1 trajectory. This corresponds with a reduced ICS effect when 
asthma and COPD patients continued smoking.[186,187,228] This reduced 
effect could be extrapolated to other noxious particles, such as chronic 
occupational exposures. Active firefighting might have acted as a modifier of 
ICS response, since active firefighting duty became stronger associated with 
ICS/LABA treatment the longer after 9/11.  
 
V.4. Drug-related factors 
As a drug-related factor, improved adherence to ICS after PC intervention 
when using real-life pharmacy claims data, led to a beneficial response to ICS 
in asthma patients. The results are in line with earlier trial results on 
community pharmacy interventions.[108,211,204,110] This confirms our 
hypothesis that adherence is an important factor for ICS response as it affects 
the expected pharmacological effect of the drug and thus the ability to treat 
the underlying disease.[97] Since adherence is a remaining hurdle in inhaler 
treatment, improving the adherence lead to more successful management of 
obstructive airway diseases, such as asthma.[8] Better asthma control scores 
were also observed in prospective research in patients with better ICS 
adherence.[104] 
Interestingly, in the WTC cohort we found that individuals with a favorable 
response of ICS on FEV1 decline had a shorter treatment duration compared 
with non-responders. In this cohort, this observed difference may be due 
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confounding by indication. Individuals with improved FEV1 and symptoms, 
might have discontinued their treatment. In this subgroup analysis to define 
ICS responder was done on individuals who initiated ICS in the first 4 years 
after 9/11, there might also be individuals with a different, more acute disease 
endotype. In that case, a shorter duration of treatment was justified. In 
contrast, in asthma patients, most patients require continued treatment as 
asthma is a chronic disease. 
 
V.5. ICS treatment on different outcomes 
The responses of ICS-containing treatments have been studied on different 
outcomes. We studied lung function decline as primary outcome, which serves 
as a risk for mortality.[229] The choice of FEV1 trajectory as the outcome was 
also based on availability of robust longitudinal data in this population. A 
proportion of WTC-exposed firefighters is experiencing a continuous 
accelerated decline in lung function without having a clear indication for 
inhaler treatment following asthma or COPD guidelines for the management 
for asthma or COPD. Therefore, our research findings are important for 
guiding the decision-making process in clinical practice in these patients. An 
increased frequency of pulmonary exacerbations was associated with 
accelerated FEV1 decline.[40,41] Since ICS treatment is effective in 
preventing exacerbations,[85,88,230] ICS use may reduce accelerated lung 
function decline.[231] However, real-life data supporting that theoretical logic 
is scarce. The effect of pharmacotherapy on FEV1 decline has been debated 
for over 20 years.[92] An important insight gained is that not only the 
trajectory of accelerated lung function decline can lead to COPD, but also the 
trajectory of reduced lung growth but age-related lung function decline.[31] 
However, we focused on accelerated FEV1 decline since at study entry WTC-
firefighters had an average FEV1 % predicted of over 100%.[46] Analyses 
from TORCH and SUMMIT trials showed an effect of ICS monotherapy 
resulting in an improvement of FEV1 decline of 13 mL/year and these from 
the SUMMIT 8 mL/year compared with placebo over the relatively short time 
span of the trials.[93,94] In TORCH ICS/LABA combination therapy had an 
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even greater beneficial effect of 16 mL/year compared with placebo.[93] Our 
observed average effect of ICS of an improvement of 2.4 mL/year on FEV1 
decline from our large observational cohort study with long term follow-up is 
less pronounced than these randomized placebo controlled trials. This is not a 
surprise since these trials studied populations with chronic, ongoing exposure 
and inflammation by smoking, which are different than the previously healthy 
WTC-exposed firefighter cohort with a proportion of ever smokers around 
25%. A recent systematic review concluded that trials up to one year of 
follow-up were more likely to report an increase in FEV1, with the general 
trend favoring ICS-containing medications compared to non-ICS-containing 
medications.[227] Studies with more than a year follow-up were more likely 
to report a decline in FEV1 with little evidence of a treatment difference 
between ICS and non-ICS containing medications. These findings highlight 
the importance of sufficient long follow-up, which was certainly the case in 
our studies with over 16 years follow-up. 
 We chose asthma control as another outcome to assess the effect of 
community pharmaceutical counseling (PC) interventions. Asthma control 
can be measured by respiratory symptoms and reliever use, whether or not 
using a standardized questionnaires and spirometry result. Poor symptom 
control is a proxy for the risk of worse outcomes, such as increased need for 
medications, hospitalization and death. In our study, the ratio of controller-to-
total (CTT) was calculated using pharmacy claims data before and after the 
PC intervention. This ratio reflects the proportion of controller medications by 
total asthma medication, including reliever therapy.[208,209] The higher this 
ratio, the better the expected asthma control. An advantage of CTT is its 
objective measuring which does not require additional participation, testing or 
time from the patient. The downside might be misclassification produced by 
poor adherence to dispensed medications. However, this would not be the 
preferred approach in US populations where automatic refill is standard, while 
we conducted this study in Belgium, where prescriptions need to be filled at 
the pharmacy. On the other hand, a short beta-agonist might be used before 
exercising, a manifestation of health. This will overestimate the use of reliever 
medication taken for poor asthma control and so underestimate the CTT and 
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asthma control. Another limitation of using the CTT is the fact that 2019 
asthma guidelines added as-needed low dose ICS combined with the long-
acting beta-agonist (LABA) formoterol for the treatment of mild 
asthma.[8,68] This would mean that the ICS and LABA do not reflect a good 
asthma control, since they were being used as relievers, but would have been 
misclassified as controllers when calculating a CTT ratio. However, this was 
not yet the case in 2017, when our data was collected. 
Other outcomes are mortality and exacerbation rate. Mortality rate, which is a 
hard end point, can be directly related to respiratory disease, but it can also be 
due to comorbidities influencing mortality independently. The IMPACT and 
ETHOS trials, studying COPD with exacerbation history, showed that triple 
therapy caused a reduction in all-cause mortality compared with 
LAMA/LABA but not with ICS/LABA.[86,87,232] Analyses of databases 
suggest an important role for ICS containing therapies in reducing mortality 
in asthma, which is challenging to proof in prospective research.[90,91] 
Patients selected with more severe disease, such as history of exacerbations, 
are expected to have a higher number of expected deaths associated. This 
study design will serve to the aim of proving a reduction in mortality. In the 
ETHOS trial, only COPD patients with a history of exacerbations were 
included to proof mortality effect.[86] Since the WTC cohort fortunately has 
a low death rate, it would be difficult to study mortality as an outcome. 
Similarly, this is the case in asthma nowadays, whereas the improvement of 
controller therapies led to a lower mortality rate.[91] Moreover, exacerbation 
rate has also been studied as an outcome, with a favorable effect of ICS/LABA 
seen in COPD patients.[85] In asthma, ICS/LABA combination was found to 
improve overall asthma control, including symptoms, lung function and 
reduced exacerbations.[88]  
 
V.6. Strengths 
The WTC-exposed cohort has the advantage of environmental exposure at a 
specific, well-defined time point. This offered us the unique opportunity to 
investigate the role of time between exposure and initiation of therapy in 
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response to treatment. Accurately estimating exposure is often challenging in 
other cohorts, such as for smoking. This can also be complicated by a long 
time window in chronic exposures. Another strength of the WTC cohort is the 
wealth of longitudinal data with little loss to follow-up, reducing the potential 
for selection bias. Using this longitudinal data, we could analyze spirometry 
and symptoms pre- but also post-initiation of treatment. In RCTs such as 
TORCH and SUMMIT, on the other hand, there are no data prior to baseline 
assessment at trial entry. Also, the duration of follow-up without significant 
dropout is quite short.[93,94] Another limitation is that these RCTs were not 
powered for the analysis of FEV1 decline because lung function was 
prespecified as a secondary outcome.[85,233] Since the treatment effect on 
the primary endpoint was not statistically significant, the statistical testing of 
FEV1 decline should be interpreted as descriptive only. Furthermore, real-life 
observational studies analyzing the effect of ICS treatment on lung function 
trajectory are lacking. Our research estimated the effect of ICS treatment on 
FEV1 trajectory using longitudinal, observational data. 
 
V.7. Limitations 
There is a limitation in generalizability with respect to the WTC cohort 
analyzed, which contained only males, who were exposed to WTC dust and 
who were active and healthy before 2002 at the time of FDNY enrollment. 
This implies that the results should be interpreted with caution for women or 
individuals with comorbidities that would preclude FDNY employment. Also, 
extrapolating the results of individuals exposed to this unique, massive dust 
exposure of 9/11 to lung injury from other causes, such as air pollution, 
biomass exposure or cigarette smoking, should be done with caution. 
 
Furthermore, there are some limitations to the completeness of data and data 
availability for observational research. Studying biomarkers in observational 
cohorts, the analyzed are limited on the number of blood draws done and 
stored serum. Despite standard blood tests including eosinophils are 
incorporated in the WTC monitoring exams, there are more lab values missing 
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than spirometries or questionnaires. Some possible explanations include that 
labs are sometimes scheduled on a different day and therefore might get 
forgotten. Also, blood draws are a little more invasive and some people might 
have anxiety to perform this test. In addition, there is a chance of 
uninterpretable lab results due to pre-analytic errors, such as wrong storage of 
the specimen, or technical errors to perform the test, such as blood cloths in 
the sample. This explains the larger numbers of missing blood eosinophils. 
For specific tests, such as IgA and IL-4, it is even more obvious that the 
number of patients with these tests, is low. This made it more challenging to 
identify biomarkers. We ended up with a very low number of people with IgA 
tested among the individuals having sufficient longitudinal spirometry 
measurement. This resulted in low power to proof an association between low 
IgA and ICS response. Finally, there might be unmeasured confounding, as in 
all observational research, due to the lack of (detail in) some data. Regarding 
active firefighting, we included active duty vs retired status as a covariate for 
the initiation for ICS-containing treatments. However, to study the actual 
influence of active firefighting as an environmental factor, we would have a 
surrogate of firefighting exposure. This could have been the number fires or 
frequency firefighters are called to a big fire, for example. Other variables that 
would ideally be of better quality are smoking, including a more accurate 
amount of pack-years. Another variable is adherence to treatment, which is 
probably overestimated as it is mainly based on pharmacy claims data with 
automated refills trough mailing. These would only stop if firefighters 
acknowledged they were not using the medication sent by mail during a 
monitoring exam. Therefore, we used a threshold of 2-year treatment duration 
in a lot of the analyses. 
 
Other limitations to the data availability, are the medication data sources, as 
in most pharmaco-epidemiologic research. First, data on pharmacy claims, 
billed through the WTC health program, was not electronically available until 
December 2006. The claim’s prescription date is the date a medication was 
filled, and is not necessarily the date of treatment administration, as assumed 
in this study. We used prescription refill as a surrogate marker for medication 
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adherence, but we had no information if and how patients took their inhaler or 
medication in the 9/11 cohort. As a second source, we used data from an 
automated search through EMR notes describing medication use. This data 
source does not capture every single time medication was taken or dispensed, 
and thus, will be specific but not sensitive in estimating the duration of 
treatment exposure.  
Also, the medication adherence calculated was dependent on the data 
sources available. As adherence measures in the Belgian nationwide study, we 
used cumulative defined daily dose (DDD)s over a year period. We compared 
the cumulative DDDs of ICS, being asthma controller medication, per patient 
one year before to the year after a pharmaceutical counseling intervention. 
Analyzing cumulative DDDs is analogous to proportion days covered, a 
commonly used parameter for adherence from pharmacy claim 
databases.[181] If the cumulative DDDs of controller medication improves, it 
can be used as a surrogate for adherence to this maintenance treatment. Since 
we did not have data on an individual level, another limitation is that we 
cannot guarantee that the gain in cumulative DDDs was exclusively due to 
increased frequency of their ICS dose (indicative for an improved overall 
adherence to ICS) and not influenced by higher doses of ICS prescribed 
(indicative for worsening severity). 
 
Finally, there are also limitations to the inverse probability of treatment 
weighting (IPTW) model used to estimate the overall effect of ICS on lung 
function trajectory. This type of propensity score method used for estimating 
the treatment effect, also has its limitations. Propensity scores are valuable in 
controlling for measured confounding in observational studies of medical 
treatments or risk factors. However, this propensity score method cannot 
control for unmeasured confounding.[197] This might explain why the ICS 
effect resulted from the IPTW model differs from the effect estimated by the 
pre-post initiation analyses. Despite the weighting, the treated and non-treated 
groups had a different average FEV1 throughout follow-up. To check if a 
different baseline FEV1 played a role in the calculated treatment effect using 
IPTW, we also performed an analysis matched on baseline covariates, during 
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the first 4 years post-9/11. Another challenge using IPTW, was estimating the 
use of other medication that could have influence on the FEV1 trajectory, such 
as oral steroids and LABAs. We added the use of those medications in the 
propensity score as a time-varying confounder. Moreover, choosing a time 
period to perform the time-varying modeling by IPTW was done arbitrary. We 
chose a 2-year period, assuming patients would have a monitoring exam every 
2 year on average. Unfortunately, we still had to deal with missing data in 
those intervals, mainly for respiratory symptoms and blood eosinophil counts 
in particular intervals. To deal with this missing data, we used imputations. 
Unfortunately, there were still many missing eosinophils counts in a certain 
time period for which we performed sensitivity analyzes without eosinophils 
in the propensity score, which did not change the overall result. In future 
research it would be important to carefully estimate the adherence to 
dispensed medicines. Preferably this would not only include the treatment 
exposure that is being studied, but all comedications that potentially alter the 
outcome as well. 
 
V.8. Conclusions 
Host, environmental and drug-related factors predictive for an optimal 
response to ICS are identified. Individuals at risk for treatment of post-9/11 
lung injury have a lower baseline FEV1 and worse respiratory symptoms. 
Also, the potentially more reversible disease endotype developed early after 
9/11 seems most ICS-responsive. Furthermore, blood biomarkers, such as 
eosinophils and IgA, drawn soon after irritant exposure may serve as a 
surrogate for host-intrinsic predisposition to develop irritant-associated lung 
injury years later. However, these biomarkers did not significantly predict 
response of ICS on accelerated lung function decline. As an environmental 
factor, continued occupational exposures may reduce the effect of response to 
ICS, when acting as modifiers. Among the drug related factors, an improved 
adherence leads to a beneficial ICS response, reflected in better disease 
control. Finally, ICS treatment among WTC-exposed individuals leads to a 
modest improvement in yearly FEV1 decline compared with non-treated. 
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To further improve the selection of a treatment to the individual patient’s 
needs, more determinants of the multifactorial interaction resulting in an 
overall ICS response need to be unraveled trough big, longitudinal data 
analyzes. 
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VI.1. Broader, international perspective – generalizability  
The 9/11 disaster is an exceptional disaster, but it was luckily accompanied by 
an excellent monitoring program and meticulous data collection. This allowed 
studying research hypotheses in a very well-phenotyped cohort with well-
documented exposure time. The very low death rate in the FDNY WTC-
exposed cohort resulted moreover in many person years of longitudinal data 
and minimized risk of survival bias. It remains a challenge to proof causality 
of 9/11 and health effects as there is no similar non-WTC-exposed FDNY 
cohort as a comparison group. The observation of an acute drop in FEV1 
strongly suggests an impact of the disaster on the lower respiratory 
system.[29,46] Our research findings may also be useful in predicting health 
consequences in future events exposing individuals to dust produced by 
catastrophes and in certain occupations. Additionally, the effect of active 
firefighting by itself is also important to take into account, since it may act as 
a modifier for ICS response. Firefighting duty has found to be associated with 
decreased pulmonary function.[234] In that perspective our findings might be 
important for all firefighters, even those without WTC exposure.  
 
Some key messages based on our research can be taken to the field of 
obstructive lung diseases. First, to study lung function decline, a long-term 
follow-up is recommended. This is also based on a systematic review 
examining ICS response on lung function decline, observing different effects 
in shorter follow-up studies (less than one year) compared with the effects in 
longer follow-up studies.[227] Additionally, in a subgroup analysis, younger 
age and lower baseline FEV1 % predicted were identified as host factors and 
never smoking as an environmental factor, were associated with beneficial 
ICS response on FEV1 trajectory. Blood eosinophils and IgA were considered 
potential biomarkers indicative of host susceptibility, but did not significantly 
identify ICS responders after WTC exposure. Given the limitations regarding 
the availability of blood data and the lack of statistical power, we cannot state 
these findings are final. Therefore, more research is needed to further explore 
these associations of potential biomarkers and lung injury. Ideally, there 
should always be a systematic baseline drawn of potential blood biomarkers, 
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including eosinophils, IgA, IgE, IL-4, prior to the initiation of ICS. It also 
highlights the challenge but continued importance of biomarker research and 
in expanding to all factors that contribute to the ultimate treatment response. 
Therefore, big data collections from treated patients, including potential 
biomarkers, remain essential to study the interplay of host, environmental and 
drug-related factors. 
 
Inverse probability of treatment weighting (IPTW) was the method used to 
analyze ICS effects from the observational data of the WTC cohort. It is a 
method that is gaining importance, since the value of observational research 
and real-world data analyses is growing. Despite the complexity and 
limitations, it reduces selection bias by equating groups based on time-varying 
confounders when analyzing treatment effects in observational data.[196] In 
addition, IPTW could also be applied to study any outcome of interest, such 
as patient reported outcome measures. In the absence of real-world studies on 
the effects of pharmacotherapy in asthma and COPD, this method could also 
be applied to cohorts of patients with asthma or COPD.  
 
VI.2. Socio-economic impact 
Medication adherence remains a persistent challenge within respiratory care. 
Since primary care physicians and pulmonologists often rely on each other, 
additional support from the pharmacist has an important place in the 
healthcare system. Pharmaceutical counseling interventions are found to be 
effective in improving controller adherence and asthma control. This leads to 
a better health outcome and consequently a decrease in the economic burden. 
Additionally, clinical pharmacist services delivered via telemedicine, mainly 
telephonic interactions, had a positive impact on disease management and 
adherence.[217] With this increasing central role pharmacists are playing 
nowadays in Anglo-Saxon countries and beyond, they can be seen as the 
guardian of medication adherence, especially in chronic respiratory patients. 
This role can be fulfilled in various ways, with or without using novel 
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technologies. Either way, the community pharmacist has the potential to have 
even more impact on patient’s health through such interventions. 
 
VI.3. Clinical relevance 
WTC-exposed firefighters with accelerated FEV1 decline especially seemed 
to benefit from ICS treatment when they initiated shortly after WTC exposure. 
This may also have therapeutical consequences for the current management 
of WTC-related lung injury. Physicians who treat WTC-exposed patients 
might consider an add-on treatment or therapeutic switch in certain 
individuals. Those could include patients with ongoing accelerated FEV1 
decline who do not experience a clinical benefit, reflected by ongoing 
respiratory symptoms, frequent exacerbations or low quality of life. Given the 
observed association of IL-4 with obstructive airways disease, therapies 
targeting IL-4 may be an alternative treatment. Dupilumab, an IL- 4/IL-13 
inhibitor, would be a reasoned choice as it showed a beneficial effect on lung 
function and exacerbations in asthma patients.[235] Studies to further 
exploring this biological are being conceptualized.  
 
VI.4. Future 
If exposure cannot be reduced to one event, or if an insidiously declining lung 
function pattern is not directly related to respiratory symptoms, identifying 
response to treatment can be challenging. Longitudinal monitoring through 
wearable devices and app- /web-based platform could collect all relevant, 
possible time-varying factors. Continuous development of new technologies 
and tools is shifting healthcare for the next generation respiratory patients 
towards e-health. Those patients are grown up with smartphones and 
electronic platforms, so that these technologies could be used. Based on our 
findings, respiratory symptoms, adherence to treatment and exposure to 
noxious particles such as smoking or occupational exposures are of interest. 
FEV1 as an important factor could be added by a handheld spirometry 
screening. In combination with biomarker data, this could facilitate 
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longitudinal data collections and the identification of more disease phenotypes 
and endotypes. In chronic patients with obstructive lung diseases, those new 
technologies could become a standard follow-up tool as part of their disease 
management. 
 
The role of inhaled corticosteroids could extend in the future to areas of 
application outside the WTC-exposed cohort or obstructive lung diseases. In 
severe pneumonia, preliminary findings that early treatment with a 
combination of an inhaled corticosteroid and a beta-agonist reduces the risk 
of respiratory failure are being examined by a multicentric clinical trial.[236] 
Furthermore, inhaled corticosteroid treatment has potentially beneficial 
effects in COVID-19, with is further investigated to date in different trials all 
over the world.[237–239] 
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VII.1.  Summary (EN) 
Treatment response is the result of a complex interaction between host factors, 
environmental factors and drug-related factors. Those factors were studied 
separately in order to obtain the best possible picture of the optimal response 
to inhaled corticosteroids (ICS). 
 
First, we characterized the type of lung injury of World Trade Center (WTC)-
exposed firefighters, identifying individuals and their characteristics. In 
Chapter III.1, host factors associated with prolonged ICS / long-acting beta-
agonist (LABA) treatment were body mass index, lower first post-
11 September 2001 (9/11) spirometry measurements and first post-9/11 
modified Medical Research Council (mMRC) dyspnea score. These 
observations were confirmed in the longitudinally analyses of Chapter III.4 
with as host characteristics lower forced expiratory volume in 1 second (FEV1) 
and symptoms of wheeze and dyspnea associated with prolonged ICS/LABA 
treatment. Worse baseline FEV1 and respiratory symptoms are host factors 
that predict response to ICS (Chapter IV.2).  
Regarding biomarkers, a higher blood eosinophil count and increase 
in IL- 4 were associated with an increased risk of irritant-induced airflow 
obstruction (Chapter III.2). Furthermore, low immunoglobulin A (IgA) soon 
after WTC exposure in Chapter III.3 was associated with lower longitudinal 
FEV1 measurements, increased risk of airflow obstruction and increased 
antibiotic treatment. However, blood eosinophils and IgA did not significantly 
predict the response to ICS on lung function decline, but low IgA tends to a 
beneficial response (Chapter IV.2). 
 
Second, the environmental factor associated with prolonged ICS/LABA 
treatment was high intensity WTC exposure defined by arrival the morning of 
9/11 (Chapter III.1). In Chapter III.4, this association was only observed 
when treatment was initiated early after 9/11, leading to the conclusion that 
determinants of treatment response may change over time.  
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Last, drug-related factors associated with response to ICS treatment were 
assessed. In a longitudinal study in Chapter IV.1, ICS treatment improved 
lung function decline in individuals with WTC-related lung injury. This 
improvement was more pronounced when WTC-exposed firefighters were 
more adherent to ICS. Pharmaceutical counseling interventions, analyzed 
through nation-wide pharmacy data in Chapter IV.2, led to a marked 
improvement in the adherence of asthma patients to ICS. This also resulted in 
an improved controller-to-total-ratio and a trend towards a reduction in the 
number of patients requiring rescue inhalers and antibiotics, indicating an 
improvement in asthma control and a lower exacerbation rate. 
 
In conclusion, to improve response to ICS, host factors and drug-related 
factors were studied. The former included characterization of disease type and 
identification of individuals at risk, and the latter included studying the impact 
of adherence. First, lower lung function and worse respiratory symptoms are 
host factors associated with ICS/LABA treatment, of which a lower FEV1 
predicts a better response to ICS. Subsequently, blood biomarkers, such as 
eosinophils and IgA, drawn soon after irritant exposure may serve as a 
surrogate for the patient-intrinsic predisposition to develop irritant-associated 
lung injury years later. However, these biomarkers do not predict the response 
of ICS on lung function decline, but low IgA tends to a beneficial response. 
Finally, improved adherence to ICS treatment leads to reduced lung function 
decline and better asthma control.  
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VII.2.  Samenvatting (NL) 
De respons op behandeling is het resultaat van een complex samenspel tussen 
gastheerfactoren, omgevingsfactoren en geneesmiddelgerelateerde factoren. 
Deze factoren werden afzonderlijk bestudeerd om een zo goed mogelijk beeld 
te krijgen van de optimale respons op inhalatiecorticosteroïden (ICS). 
 
Ten eerste hebben we het type longaandoening van aan 11 september 2001 
(9/11)-blootgestelde brandweermannen gekarakteriseerd door individuen en 
hun kenmerken te identificeren. In Hoofdstuk III.1 waren gastheerfactoren 
geassocieerd met langdurige behandeling met ICS/langwerkende bèta-
agonisten (LABA), de body mass index, lagere eerste post-9/11 
spirometriewaarden en gemodificeerde Medical Research Council (mMRC) 
score voor kortademigheid. Deze waarnemingen werden bevestigd in de 
longitudinale analyses van Hoofdstuk III.4 met als gastheerkarakteristieken 
een lagere éénsecondewaarde en symptomen van piepende ademhaling en 
kortademigheid die geassocieerd waren met langdurige ICS/LABA 
behandeling. Slechtere baseline éénsecondewaarde en 
ademhalingssymptomen zijn gastheerfactoren die de respons op ICS 
voorspellen (Hoofdstuk IV.2).  
Wat betreft bloedbiomarkers waren een hoger aantal bloed-
eosinofielen en een toename van IL-4 geassocieerd met een verhoogd risico 
op sommige endotypes van irritatie-geïnduceerde luchtwegobstructie 
(Hoofdstuk III.2). Bovendien was verlaagd immunoglobuline A (IgA) kort 
na 9/11 blootstelling in Hoofdstuk III.3 geassocieerd met een lagere 
longitudinale éénsecondewaarde, een verhoogd risico op luchtwegobstructie 
en meer antibioticabehandeling. Blood eosinofielen en IgA werden echter niet 
significant bevonden in het voorspellen van de ICS respons op longfunctie 
achteruitgang, maar verlaagd IgA neigde wel tot een gunstige respons. 
(Hoofdstuk IV.2). 
 
Ten tweede was blootstelling aan 9/11 met hoge intensiteit, gedefinieerd door 
aankomst de ochtend van 9/11, de omgevingsfactor geassocieerd met 
langdurige ICS/LABA behandeling (Hoofdstuk III.1). In Hoofdstuk III.4 
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werd deze associatie alleen bevestigd als de behandeling kort na 9/11 werd 
gestart, wat leidde tot de conclusie dat determinanten van respons op 
behandeling in de loop van de tijd kunnen veranderen.  
 
 
Als laatste werden geneesmiddelgerelateerde factoren geassocieerd met de 
respons op ICS behandeling, beoordeeld. In een longitudinale studie in 
Hoofdstuk IV.1, verbeterde ICS behandeling de achteruitgang van de 
longfunctie bij personen met 9/11-gerelateerde longaandoeningen. Deze 
verbetering was meer uitgesproken wanneer de brandweermannen meer 
therapietrouw waren. Farmaceutische counseling-interventies, geanalyseerd 
aan de hand van nationale apotheekgegevens in Hoofdstuk IV.2, resulteerden 
in een duidelijke verbetering van de therapietrouw aan ICS in astmapatiënten. 
Dit resulteerde ook in een verbeterde controller-to-total ratio en een trend in 
de richting van een vermindering van het aantal patiënten dat noodmedicatie 
en antibiotica nodig heeft, hetgeen duidt op een verbetering van de 
astmacontrole en een daling in exacerbaties. 
 
Concluderend dat, ter verbetering van de respons op ICS, gastheerfactoren en 
geneesmiddelgerelateerde factoren werden bestudeerd. De eerste betrof 
karakterisering van onderliggende ziekte en identificatie van personen die 
risico lopen, en de laatste betrof het bestuderen van de impact van 
therapietrouw. Ten eerste zijn een lagere longfunctie en meer respiratoire 
klachten, gastheerfactoren die geassocieerd zijn met ICS/LABA behandeling, 
waarvan een lagere éénsecondewaarde voorspellend is voor een betere 
respons op ICS. Vervolgens kunnen bloedbiomarkers, zoals eosinofielen en 
IgA, kort na 9/11 blootstelling afgenomen, dienen als een surrogaat voor de 
intrinsieke aanleg van de patiënt om jaren later een longaandoening te 
ontwikkelen. Deze biomarkers voorspellen echter niet de respons van ICS op 
longfunctie achteruitgang, hoewel IgA neigt naar een gunstige respons. Ten 
slotte leidt een betere therapietrouw aan ICS behandeling tot een verminderde 
achteruitgang van de longfunctie en een betere astma controle.  
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